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Purna Krishnamurthy  
 
PARP14 IN ALLERGIC INFLAMMATION 
 
Allergic inflammation is a result of damaging immune responses stimulated by 
innocuous proteins and is mediated by a complex interplay between 
inflammatory cells including eosinophils, basophils, neutrophils, mast cells, 
dendritic cells and lymphocytes. The anatomic location of allergic inflammation 
determines the structural cells that become targets, such as airway smooth 
muscle cells, mucous secreting cells, keratinocytes, and other epithelial cells. 
The cytokine IL-4 is critical for this process and promotes activation of the 
transcription factor STAT6 and transcriptional co-factors that regulate pro-allergic 
gene expression. STAT6 is required for IL-4 mediated responses, Th2 cell 
differentiation and class switching to IgE and has been implicated in the 
progression of asthma, atopic dermatitis (AD), and eosinophilic esophagitis 
(EoE). STAT6 interacts with the co-factor Poly-ADP ribose polymerse-14 (PARP-
14 or ARTD8), one of 17 PARPs with ADP-ribosyl transferase activity. PARP14 
was initially identified as a transcriptional co-activator for STAT6, and PARP14 
and the enzymatic activity associated with it promote Th2 cell differentiation. 
Allergic airway disease is attenuated in Parp14-/- mice or in mice treated with 
PARP inhibitor, PJ34. To study the role of PARP14 in EoE, we examined 
esophageal biopsies from children and demonstrated a correlation between the 
expression of eosinophilic chemo-attractant, CCL26 and PARP14. To study 
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allergic skin inflammation, we used a mouse model of spontaneous inflammation 
(Stat6VT mice). We generated Stat6VTxParp14-/- mice and observed that 
Stat6VTxParp14-/- mice develop more severe AD-like lesions with increased 
morbidity compared to Stat6VT mice. However, PARP14 is not required in 
keratinocytes to mediate the expression of IL4 and Stat6 responsive genes 
important for skin barrier function, suggesting that PARP14 contributes to a 
hematopoietic cell-intrinsic function. Thus, the data suggests that PARP14 
serves specific roles in allergic disease that vary with the target organ.  
 
Mark H Kaplan, Ph.D. - Chair 
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INTRODUCTION 
 
Immune System 
The function of the immune system is to defend the body against infectious 
microbes. Components of microbes as well as macromolecules, such as 
proteins, polysaccharides and small chemicals that are recognized as foreign can 
elicit an immune response. Innate and the adaptive immunity form important 
aspects of the immune system that work together to generate effective protective 
responses against infectious pathogens.  
 
Innate Immunity 
Innate immunity provides the early line of defense; the defense mechanisms are 
in place before an infection and respond rapidly to an infection. Skin provides a 
physical barrier and forms the first line of defense. In addition to forming a 
physical barrier, the enzymes (anti-microbial peptides) produced by the skin can 
kill microbes and the cytokines produced can promote and regulate immune 
responses (1). Epithelial cells held together by tight junctions line the 
gastrointestinal, respiratory and urogenital tracts. Internal epithelia is coated with 
mucous that prevents the adhesion of microorganisms, and cilia on epithelial cell 
layers in the respiratory, urogenital and gastrointestinal tracts help to 
continuously expel mucous and microorganisms. When this barrier is broken, 
microorganisms can cross the epithelial barrier where various immune cells then 
recognize and try to eliminate the pathogen. Cell mediated immunity of the innate 
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immune system is mediated by phagocytes – macrophages, neutrophils, 
dendritic cells (DCs), and cells that release inflammatory mediators – mast cells, 
basophils, eosinophils, natural killer cells (NK cells) (2). 
 
Cells of the innate immune system recognize certain highly conserved structures 
on the surface of microorganisms referred to as pathogen associated molecular 
patterns (PAMPs) (eg. LPS, double stranded RNA, mannans). PAMPs are 
recognized by pathogen recognition receptors (PRRs) on the surface of 
macrophages, dendritic cells and neutrophils. Recognition of a PAMP by PRR on 
macrophages leads to phagocytosis and killing of the pathogen. Neutrophils 
migrate to site of infection within a few hours of pathogen entry and like 
macrophages, sequester and destroy microbes. Eosinophils and basophils carry 
cytoplasmic granules containing cytokines and cytotoxic proteins that are 
released into the extracellular space for defense against parasites. Mast cells 
provide defense against helminths by degranulating thereby releasing 
proinflammatory substances including cytokines, acidic proteoglycans and 
histamine. They also release inflammatory mediators like cytokines and 
chemotactic factors that attract other immune cells to the site of inflammation and 
enhance the immune response. Unlike other cells that recognize pathogen via 
PAMPs, NK cells lack antigen specific receptors. NK cells monitor the expression 
of major histocompatibility complex class I (MHC I) on all nucleated cells and kill 
virus-infected cells and tumor cells that downregulate MHC I. Immature dendritic 
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cells (DCs) are also capable of phagocytosis of pathogens upon recognition of 
PAMPs. Mature DCs then present antigens to T-cells in the lymph nodes (3).  
 
Adaptive immunity 
Unlike innate immune pathways that are activated relatively rapidly, the adaptive 
immune responses become effective only after several days and show great 
specificity to target antigens. T cells express αβ T cell receptor (TCR), the 
majority express αβ TCR, while others γδ TCR. T - and B-cells develop antigen 
specificity via somatic rearrangement within T cell receptor (TCR) and B cell 
receptor (BCR) genes. This results in a pool of lymphocytes expressing a diverse 
repertoire of antigen specific receptors.  
 
Professional antigen presenting cells (APCs) such as dendritic cells, 
macrophages and B-cells break down foreign protein into peptides that are then 
loaded on MHC molecules and presented on cell surface. Upon interaction of 
naïve T cells with APC expressing MHC-peptide complex along with co-
stimulatory signals- CD80 and CD86, T cells become activated. CD4+ T cells 
recognize peptides presented on MHC class II molecules whereas CD8+ T cells 
recognize peptides presented on MHC class I molecules.  
 
Upon activation, naïve CD4+ T cells undergo clonal expansion and differentiation 
into effector T cells. The specific cytokine milieu encountered by naïve T cels 
determines which subset of T helper cells develops (e.g. Th1, Th2, Th9, Th17, 
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Treg or Tfh cells). These subsets are often characterized by the cytokines they 
secrete and the immune response they elicit. Th1 cells secrete IFNγ and TNF-α. 
These cytokines are important in mediating host defense against intracellular 
pathogens. However Th1 cells can also cause autoimmune diseases. Th2 cells 
secrete IL-4, IL-5 and IL-13 and are important for immunity to extracellular 
pathogens and allergic disease. Th9 cells are characterized by IL-9, IL-10 and IL-
21 production and are important to clear extracellular pathogens and mediate 
allergic diseases. Th17 cells secrete IL-17A, IL-17F, IL-21 and IL-22 and are 
important for host defense against bacterial and fungal pathogens; they also 
mediate autoimmunity and allergic diseases. Treg cells secrete IL-10, TGF-β and 
IL-2 and are responsible for establishing immune tolerance. Treg cells can be 
sub-classified into those that differentiate in the thymus (tTreg cells), the 
periphery (pTreg cells) and in vitro (iTreg cells). Tfh cells secrete IL-21 and IL-4 
and are important in humoral immunity by activating follicular B cells in lymphoid 
tissues (3, 4). 
 
Peptide antigens presented on MHC class I molecules activate CD8 T cells, also 
referred to as cytotoxic T cells (CTL). CTLs contain cytoplasmic granules filled 
with toxic proteins like granzymes and perforins. When CTLs recognize cells 
bearing non-self antigens such as virus infected cells or tumor cells, toxins from 
the granules are released only in the direction of the target cells by the formation 
of an immune synapse, thus avoiding damage to healthy neighboring cells (2).  
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Similar to T cells, naïve B cells, upon antigen binding to BCR, get activated. Both 
protein and non-protein antigens stimulate antibody responses. Naïve mature B 
cells express surface IgM and IgD. B cell responses to protein antigens require 
involvement of a CD4+ helper T cell specific for that antigen. Activated T cells 
express CD40L that engages with CD40 expressed on B cells. Cytokines 
secreted by these T cells bind to cytokine receptors on B cells. This stimulates B 
cell proliferation and differentiation. Some of the B cells undergo isotype class 
switching leading to the generation of various immunoglobulin (Ig) isotypes. 
Isotype class switching is regulated by cytokines produced by T helper cells that 
are activated in response to the microbes.  The immunoglobulin isotypes are IgD, 
IgM, IgG, IgE and IgA, with IgG and IgA further classified into subclasses each 
with distinct effector functions. Affinity maturation leads to the generation of 
antibodies with increased affinity for a particular antigen, and results in 
antibodies, which more efficiently bind to, neutralize and eliminate microbes. B 
cell activation can lead to the selective survival of B cells producing antibodies 
with the highest affinity (3,5).  
 
Th2 cells 
Th2 (T helper type 2) cells secrete IL-4, IL-5, IL-9, IL-10 and IL-13. Th2 cells 
mediate host defense against extracellular pathogens, such as helminths. Th2 
cells also mediate allergic disease like asthma and atopic dermatitis and play an 
important role in disease pathology. T cells can be polarized in vitro by IL-4 into 
Th2 cells. IL-4 signaling through the IL-4R, leads to the phosphorylation and 
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homodimerization of STAT6. IL-4 via STAT6 upregulates the expression of 
GATA3, the master transcription regulator of Th2 cell differentiation. STAT6-
independent pathways, such as Notch signaling pathway, Wnt signaling pathway 
through β-catenin and T-cell factor 1 (TCF-1) can also promote GATA3 
expression. IL-2 activation of STAT5 is also crucial for Th2 cell differentiation in 
vitro. In addition to STAT6, STAT5 and STAT3 are also important for Th2 cell 
differentiation. STAT5 binds to regions on the Il4 locus and in combination with 
GATA3, STAT5 can induce IL-4 expression. STAT3 also becomes activated 
during Th2 differentiation and STAT3 is required for STAT6 ability to bind to 
target genes (6).  Epithelial cells are a source of cytokines such as Thymic 
stromal lymphopoietin (TSLP), IL-25 and IL-33. These cytokines also contribute 
to type 2 immune responses (7).  
 
IL-4 induces B cell class switching to IgG1 and IgE. IL-4 induces class switching 
to IgE and IgE can bind to high affinity Fc receptors (FcεRI) on mast cells, 
basophils and eosinophils. Binding of antigen to IgE, cross-links IgE bound to its 
receptor resulting in activation and degranulation of these cells. Upon activation, 
mast cells and basophils secrete inflammatory mediators such as histamine, 
chemokines, cytokines and lipid mediators like prostaglandins and leukotrienes. 
IgE-dependent mast cell activation in the gastrointestinal tract promotes 
expulsion of parasites by increasing peristalsis and mucus secretion. In mucosal 
tissues, IL-5 can promote recruitment of eosinophils, and IL-9 produced can 
recruit mast cells, resulting in tissue eosinophilia and mast cell hyperplasia, 
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respectively. IL-4, IL-9 and IL-13 can act directly on epithelial cells and smooth 
muscles leading to goblet cell hyperplasia, mucous production. Th2 immune 
responses can cause airway hyperresponsiveness (AHR) in the lung and can 
cause barrier dysfunction in the skin and esophagus. Thus, though Th2 mediated 
responses are important for host immunity, they can also be harmful to the host 
(7).  
 
STAT6 
STATs (Signal Transducer and Activator of Transcription) are latent cytoplasmic 
transcription factors that activate gene transcription in response to cytokines. In 
response to extracellular cytokine signals and growth factors, STAT proteins 
undergo tyrosine phosphorylation and are involved in many different regulatory 
events such as hematopoiesis, immunomodulation and development (8). 
Phosphorylated STAT6 is transported to the nucleus, where along with co-
factors, STAT6 regulates the expression of genes that are involved in allergic 
inflammatory responses. Upon exposure to an environmental allergen, epithelial 
cells in the airways, esophagus and the keratinocytes in the skin secrete 
cytokines that initiate the development of an immune response (9). Chronic 
challenge with allergen results in organ-specific diseases such as asthma or food 
allergy that are characterized by pulmonary and gastrointestinal inflammation 
respectively. 
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Signal transducer and activator of transcription 6 (STAT6) is a member of the 
STAT family of proteins, which consists of STAT1, 2, 3, 4, 5A, 5B and 6. Human 
STAT6 is located on chromosome 12q13.3. The cytokines IL-4 and IL-13 activate 
STAT6 (10). The type I IL-4 receptor is composed of the common gamma chain 
(γc) and the IL4Rα chain and binds only IL-4. The type-II IL-4 receptor is 
composed of IL4Rα chain and IL13Rα1 chain and binds to and transmits signals 
of both IL-4 and IL-13. Three central tyrosine residues in IL4Rα chain (Y575, 
Y603 and Y631) become phosphorylated by stimulation of the receptor and are 
important for the activation of STAT6. These phosphotyrosines on the receptor 
chain become docking sites for SH2 domains of STAT6 monomers. The SH2 
domains then get tyrosine phosphorylated themselves by receptor associated 
Jak kinases (Jak1 & 3). This allows for dimerization of STAT proteins via their 
SH2 domains. The resulting STAT6 dimer can now migrate to the nucleus where 
it can bind DNA directly (11–13) 
 
Early studies in Stat6-/- mice showed that STAT6 is involved in IL-4 mediated 
functions including Th2 cell differentiation, class switching to IgE and expression 
of cell surface markers such as MHC-II and CD23 (14–16). STAT6 regulates the 
expression of Gata-3, and Gata-3 reconstitutes Th2 development in STAT6-
deficient T cells, making it a critical factor for Th2 cell differentiation and function 
(17). 
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Mechanisms of STAT6-dependent gene regulation  
The protein structure and domain organization of STAT6 includes the N-terminal 
domain that is involved in dimerization, coiled-coil domain required for interaction 
with other proteins, DNA binding domain, SH2 domain (src homology domain) 
that interacts with phosphorylated tyrosine residues in the receptor and the 
transactivation domain at the C-terminal. STAT6 preferentially binds to 
TTCN4GAA sequence and activates gene transcription. STAT6 recruits specific 
sets of co-activators to provide specificity for promoter activation (12). STAT6 
recruits co-activators such as CBP/p300 and NCoAs to activate gene expression 
by providing histone acetyltransferase (HAT) activity. PARP14 has been 
identified to be one such co-factor that associates with STAT6 and regulates 
gene expression.  
 
PARPs 
Poly (ADP–ribose) polymerases (PARPs) family of proteins contains 17 
homologues, of which PARP1 is the founding member. PARPs are enzymes that 
catalyze the transfer of ADP ribose moieties from donor NAD+ molecules to 
target proteins although members of the family vary in their enzymatic abilities. 
Mono- and poly- ADP ribosylation is a protein modification that impacts the 
regulation of transcription, cell proliferation, apoptosis, signaling cascades and 
cell differentiation.  Since the catalytic product of many of the members is unclear 
and some don’t have a catalytic activity, a new nomenclature was proposed. 
Based on the type of enzymatic reaction and on structural features, PARP family 
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members are now referred to as ADP-ribosyl transferase Diphtheria-toxin like 
(ARTD) family of proteins (18).  
 
PARPs are well studied in DNA damage and cancer. As shown by Catalogue of 
somatic mutations in cancer (COSMIC), there are four known mutations in 
PARP14 that have been implicated in cancer. The mutations are – c.4754A>G 
(Pancreas, carcinoma), c.2780T>G (Endometrium, carcinoma), c.1308G>A 
(Large intestine, carcinoma), c.1698C>G (Urinary tract, carcinoma).  Though no 
mutations or SNPs have been related to allergic inflammation. 
 
Of the 17 PARP family members, PARP1 is the most extensively studied. 
Reports using PARP inhibitors and knockout mice have shown that, in addition to 
its role in surveillance and maintaining genome integrity, PARP1 also functions in 
inflammatory diseases by triggering cell death in injured tissue (19).  PARP 
family members including PARP1 and PARP2 are involved in T cell development 
in the thymus and in the periphery (20, 21). PARP1 regulates T cell activation 
and absence of PARP1 alters expression of genes and chemokines that are 
involved in maintaining Th1-Th2 balance (22). PARP1 and PARP14 have been 
studied to have a role in allergic inflammation.  
 
PARP1 (ARTD1) and allergic inflammation 
PARP1 was originally characterized for its role as a DNA damage sensor and its 
function in DNA repair. More recently, PARP1 has been identified for its role in 
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transcription, chromatin structure modification, cell death pathways and in the 
mitotic apparatus among many others, thus having outcomes in carcinogenesis, 
genome maintenance, inflammation, neuronal function and aging (23).  PARP1 
participates in inflammation by directly or indirectly regulating the expression of 
inflammatory factors including cytokines, adhesion molecules and iNOS (24). 
Inflammation in the lung or any other organ causes an increase in PARP 
expression. PARP1 has emerged as a critical player in the development and the 
progression of allergic airway disease. Animal models of allergen (Ovalbumin; 
Ova) induced airway inflammation elucidates the positive involvement of PARP1 
in airway inflammation and airway hyper responsiveness (AHR) (25, 26).  
 
In an Ova triggered model of asthma, Parp1-/- mice and mice treated using 
pharmacological PARP inhibitors to target PARP1 had diminished inflammation 
with diminished infiltration of inflammatory cells into the lung, reducing AHR and 
mucus secretion (25–28). This protective effect in the absence of PARP1 is 
attributed to inhibition of NF-κB activation and the regulated expression of 
molecules like TNF-α, iNOS and NFATc (25, 29). Decreases in the amount of IL-
5 were linked to reductions in the number of eosinophils infiltrating the lung of 
Parp1-/- mice, suggesting that PARP1 regulates IL-5 production (24). The 
absence of PARP1 or its enzymatic activity severely decreases STAT6 protein 
without having an effect on STAT6 mRNA levels. STAT6 protein degradation was 
allergen stimulated and mediated by calpain as observed in an asthma model in 
Parp1-/- mice. This in turn results in reduced IL-5 levels, decreased eosinophilia 
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and lung inflammation (30). Together, studies of PARP1 in models of asthma 
suggest that PARP1 directly regulates STAT6 and its absence can mitigate all 
signs of inflammation.   
 
PARP14 (ARTD8) and allergic inflammation 
PARP family members are classified into sub-families based on their domain 
architecture. One such sub-family is macro-PARPs that include PARP9, PARP14 
and PARP15. Members of this family contain repeats of a domain found in the 
non-histone-like region of variant histone macroH2A (31, 32). PARP14 is 
enzymatically active and catalyzes mono-ADP ribosylation. Studies from many 
labs have shown that PARP14 functions in transcriptional regulation, signal 
transduction pathways and in actin cytoskeleton regulation (33). PARP14 lacks 
the conventional transcriptional co-regulator domains such as HAT, Bromo, 
Chromo, SET or ATPase domains.  
 
PARP14 associates with STAT6 in the presence or the absence of IL-4, but not 
with STAT1, and brings about transcriptional enhancement to IL-4 dependent 
and not IFNγ dependent gene activation (Figure 1) (34). Although the macro 
domains of histone macro H2A are known to participate in gene silencing, the 
macro domains of PARP14 interact with STAT6 and increase IL-4 induced gene 
expression (34). PARP14 and its associated PARP catalytic activity can mono-
ADP-ribosylate itself and a STAT6 co-activator, p100 (Figure 4). The enzymatic 
activity of PARP14 is required to enhance gene transcription. Most PARP 
inhibitors function as competitive inhibitors, as they occupy the NAD binding site 
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within the catalytic domain of the enzyme. Blocking PARP activity using 
pharmacological inhibitors blocked IL-4 dependent gene transcription in vivo (35). 
Studies show that PARP14 regulates STAT6-dependent gene transcription by 
functioning as a transcriptional switch. Under non-stimulating conditions, 
PARP14 binds to STAT6-responsive promoters and recruits HDAC2 and 3 and 
represses gene transcription. Upon IL-4 stimulation and STAT6 activation, the 
catalytic activity of PARP14 is increased resulting in ADP-ribosylation of itself 
and HDACs. The HDAC repressor complex leaves the promoter relieving gene 
repression and making the promoter more accessible to histone acetyl 
transferases (CBP/p300, NCoA-1 and NCoA-3) and increase gene transcription 
(Figure 1) (36). As PARP14 functions as a transcriptional switch for STAT6 
dependent gene transcription, naïve T cells from Parp14-/- mice cultured under 
Th2 conditions secrete reduced amounts of Th2 cytokines IL-4, IL-5 and IL-13 
(37). Inhibiting PARP enzymatic activity using a pharmacological inhibitor 
confirmed a dose dependent reduction in Th2 cytokines, with similar amounts of 
IFNγ produced from Th1 skewed cells (37). The mechanism for promoting Th2 
differentiation is based on the ability of PARP14 or its enzymatic activity to 
regulate the binding of STAT6 to the Gata3 promoter. In a model of allergic 
airway disease (AAD), Parp14-/- mice have reduced numbers of inflammatory 
cells in BAL and reduced AHR. 
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Figure 1. PARP14 (ARTD8) and its enzymatic activity functions as an 
activator of STAT6. In the presence of IL-4, PARP14 mono-ADP ribosylates 
histone deacetylase-2 and -3 (HDAC-2 and HDAC-3), leading to their 
dissociation from the IL-4 responsive promoter. This allows STAT6 and 
transcription co-factors such as p100 to bind to the promoter, resulting in active 
gene transcription. 
 
Until recently, the role of PARP14 in other T helper cell subset differentiation and 
development was not known.  Th17 cells are defined by their ability to produce 
IL-17A, IL-17F and IL-22 and to a lesser degree TNF and IL-6. They play a 
pivotal role in host defense and in induction and propagation of autoimmunity 
(38). Increases in IL-17A are correlated with increases in neutrophil recruitment 
	 15 
and airway resistance in patients with asthma (39). T follicular helper (Tfh) cells 
are responsible for providing cognate help to B cells during formation of germinal 
centers. CD4 Tfh cells secrete IL-4, IL-10 and IL-21. IL-21 is required for 
germinal center formation for T-cell dependent antigens (40). Tfh cells are 
essential for IgE production and play an important role in allergic responses (41).  
ChIP-Seq analysis of wild-type and Parp14-/- Th2 cells identified that PARP14 
along with its enzymatic activity regulated the expression of Il21, and IL-21 
promotes Th17 and Tfh development and function (42). It was also identified 
from the ChIP-Seq data that the expression of a number genes were dependent 
on the enzymatic activity of PARP14 but were not regulated by STAT6, 
suggesting that PARP14 has STAT6-independent functions (42). Upon further 
studies, in vitro Parp14-/- Th17 cells had reduced frequency of IL-17A and IL-17F 
positive cells. Decreased frequencies of IL-17A and IL-17F were also observed 
when PARP catalytic activity was inhibited using PARP inhibitor, PJ34. In vivo in 
a model of AAD, Parp14-/- mice had decreased numbers of IL-17A+ CD4 cells 
and reduced IL-17A concentrations from antigen-stimulated splenocytes. 
PARP14 regulates Maf and Irf4 that are important transcription factors for Tfh 
development. Diminished Tfh and GC B cell frequency and numbers were 
observed in Parp14-/- mice in response to sheep red blood cell (SRBC) and 
influenza virus immunizations with decreased titres of SRBC-specific IgG. This 
has been attributed to decreased STAT3 phosphorylation potentially due to 
reduced IL-6 receptor alpha (Il6ra) expression in both Th17 and Tfh cells (43).  
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PARP14 and its enzymatic activity also have functions in other cell types. In B-
cells, PARP14 is required to maintain the balance of B-cell subsets in the spleen 
and in generating IgA responses to antigen. PARP14 induces the expression of 
B-cell survival factors such as Pim-1 and Mcl-1 and protects IL-4 treated cells 
from apoptosis (44). PARP14 deficient mice have significantly reduced numbers 
and frequency of Tfh cells. Tfh cells promote GC B cell development and a 45% 
reduction in the numbers and frequency of GC B cells was observed along with 
reductions in serum IgG1 and IgG2a/c titres in PARP14 deficient mice in 
response to SRBC immunizations. These could either be B-cell intrinsic effects or 
extrinsic mechanisms due to reduced Tfh numbers (43).  Epithelial cells express 
PARP14 and this pathway has a significant role in airway epithelial cells where 
PARP14 deficient mice subjected to Ova induced AAD had diminished AHR (37). 
In esophageal epithelial cells, STAT6 regulates the expression of eotaxin-3 and it 
is found to be dramatically increased in patients with EoE (45, 46).  PARP14 
expression is increased in EoE biopsy samples with a positive correlation to 
eotaxin-3 expression, which was entirely dependent on STAT6 binding to 
eotaxin-3 promoter (47). Inhibiting the enzymatic activity of PARP14 in human 
esophageal epithelial cells cultured with IL4 and/or IL13, decreased the 
expression of eosinophil chemoattractant – eotaxin-3 (CCL26) (47). 
Keratinocytes, which are highly specialized epithelial cells also express PARP14.  
 
Contrasting the roles of PARP1 and PARP14 in allergic airway inflammation 
In T cells, PARP1 has also been shown to modulate transcription factors such as 
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STAT6, NFAT and NF-κB (25, 29), while PARP14 primarily regulates STAT6 
gene expression (36) and the activation of STAT3 (43). Though PARP1 and 
PARP14 seem to play similar roles in STAT6-mediated allergic inflammation, 
they regulate GATA3 gene expression and hence Th2 differentiation in very 
different ways. In the absence of PARP1, calpain mediates the degradation of 
STAT6 to reduce protein concentration within the cell (30), whereas in the 
absence of PARP14, HDACs remain bound to the Gata3 promoter, inhibiting 
gene expression (87). The absence of PARP14 and its enzymatic activity 
resulted in a reduced expression of IL17A, IL17F and IL21 (36), whereas the 
absence of PARP1 has no effect on IL17 production (48). Lung cells of Ova 
challenged Parp1-/- mice fail to synthesize GM-CSF and IL-5 resulting in impaired 
eosinophil recruitment (24). In comparison, the significant reduction in lung 
eosinophilia in Parp14-/- mice is attributed to the decrease in expression of 
CCL24 (37). The production of IL-4 was inhibited to a much lower extent 
compared to IL-5 and IL-13 by PARP-1 inhibition (24). While there was a positive 
correlation between PARP14 and CCL26 expression in EoE patient biopsies, the 
same was not observed between PARP1 and CCL26 (47). Together, these 
studies suggest that PARP1 and PARP14 interact with different partners and 
regulate inflammation through independent functions.  
 
STAT6 plays varied functions in allergic inflammation both in immune cells and in 
resident tissue cells such as airway, esophageal, and intestinal epithelial cells, 
and keratinocytes (Figure 2). Current therapies to treat allergic disease are 
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targeted towards disease symptoms rather than the causative factor. Since 
STAT6 plays a pivotal role in allergic diseases, targeting the function of STAT6 
has been an appealing therapeutic strategy. Along with STAT6, inhibiting the 
transcriptional co-activator PARP14 would be helpful. PARP inhibition might have 
beneficial effects in inflammatory conditions such as asthma (24, 28) and contact 
hypersensitivity (49, 50). In a mouse model of AAD, Parp14-/- mice have 
decreased lung inflammation, airway hyper responsiveness and serum IgE (37). 
Administering a pharmacological PARP inhibitor – PJ34 (that inhibits the 
enzymatic activity of PARPs) to wild-type mice that were subjected to AAD, 
reduced the severity of airway hyperesponsiveness and lung inflammation along 
with a reduction in the Th2 responses. Administering PJ34 either during 
challenge or sensitization and challenge or multiple times during the sensitization 
phase were effective (37). Recent studies show that PARP14 is required for 
STAT3 activation (43), suggesting that it could be a potential therapeutic target 
not only for allergic inflammation but also in other immune responses where this 
signaling pathway is important. The studies in this dissertation are focused on 
gaining a better understanding of the function of PARP14 in allergic 
inflammation. 
 
As allergic airway disease is attenuated in Parp14-/- mice or in mice treated with 
PARP inhibitor, PJ34, in this dissertation we study the role of PARP14 in allergic 
inflammation of the esophagus (eosinophilic esophagitis, EoE) and of the skin 
(atopic dermatitis, AD).  
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Figure 2. Function of PARP14 and STAT6 in allergic inflammation. Although 
the studies on PARP14 are still emerging, this figure illustrates the function of 
PARP14 and STAT6 in asthma, atopic dermatitis, eosinophilic esophagitis and 
food allergy. 
 
Esophagus physiology 
The esophagus is a tubular muscular structure connecting the throat with the 
stomach and is approximately 8-10 cm at birth and 18-26 cm in adults. The 
primary function of the esophagus is to propel the swallowed food, fluids and 
saliva from the throat into the stomach. A bundle of muscles at the upper end of 
the esophagus constitutes the upper esophageal sphincter (UES), is under 
conscious control and used during breathing, eating, vomiting and belching. 
Lower esophageal sphincter (LES) is a bundle of muscles located at the lower 
end of the esophagus, where the esophagus meets the stomach. LES muscles 
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are not under voluntary control and prevent the backward flow of stomach acids 
and contents (51).  
 
The esophageal wall is composed of mucosa, submucosa and muscularis 
propria. The mucosa is made up of stratified squamous epithelial cells, the 
submucosa contains the esophageal glands and the muscularis propria is 
composed of the striated and the smooth muscle. The secretions of the 
esophageal submucosal glands are involved in mucosal clearance, peristalsis 
and salivary secretion.  
 
Defense provided by the esophagus to injury due to acid refluxate include luminal 
acid clearance and tissue resistance. Tissue resistance is a term that is used for 
all structural and functional components of the esophagus that withstand contact 
with the luminal acid. Mucous layer, unstirred water and bicarbonate ions 
comprise the pre-epithelial defense of tissue resistance. The esophageal mucosa 
consists of 30 cell layers of keratinized stratified squamous epithelium with three 
functional regions: stratum corneum, stratum spinosum and stratum 
germinativum. These epithelial layers form a part of the epithelial defense of 
tissue resistance. The uppermost seven to eight layers of cells comprises the 
stratum corneum that is designed to protect against luminal contents. Apical cell 
membranes and adjacent intercellular cell junctions such as tight junctions and 
zonula adherens provide barrier function.  
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Acid from the lumen can destroy the epithelium by crossing the cell membrane to 
lower the cytosolic pH and sustain the acidic pH long enough to destroy cell 
respiration. Acid from the lumen can also enter the cell cytosol from across the 
junctional complex into the intercellular space and then across the basolateral 
membrane. This increase in junctional permeability leads to the development of 
dilated intercellular spaces within the epithelium. Post-epithelial defense is 
provided by the blood supply to the esophageal epithelium. Along with nutrients 
and oxygen provided to the epithelium for cellular function and repair, the blood 
also brings in bicarbonates that neutralize the acid in the intercellular spaces. 
Dilated intercellular spaces are observed in acid exposed esophageal epithelium. 
Prolonged acidification of the cytosol can lead to cell injury as reflected by cell 
swelling.  
 
Cells of the lower layers, that is, stratum germinativum, are capable of replication 
and repair the injured epithelia. Replication is shown to begin 30 minutes after 
acid exposure. Repair of the epithelia is stimulated by epidermal growth factor, 
hepatocyte growth factor and insulin-like growth factor.  Cell turn over in the 
esophageal epithelium is 5 to 8 days (52).  
 
In susceptible individuals, eosinophilic esophagitis (EoE) is triggered by an 
immune response to antigens acquired via food or inhalation of environmental 
antigens. Recognition of these antigens leads to a series of cytokine-mediated 
immune responses resulting in the infiltration of eosinophils, basal zone 
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hyperplasia and subepithelial fibrosis with increased collagen deposition. 
Microscopic structural changes to the esophagus leads to some of the symptoms 
of EoE – food impaction, dysphagia and chest or abdominal pain.  
 
Eosinophilic Esophagitis 
Eosinophilic esophagitis (EoE) is a chronic inflammation of the esophagus and 
an emerging disease worldwide with a high rate of associated atopic disease 
(53). It is currently defined as a chronic, immune-mediated or antigen-mediated 
esophageal disease that is characterized by esophageal dysfunction and 
eosinophil-predominant inflammation. The dominant antigens that mediate 
disease are food based. Children present with food impaction, dysphagia and 
have esophageal mucosal eosinophilia of >15 eosinophils per high power field 
(scale – 0.04mm). Other histological features include aggregates of eosinophils 
and eosinophil layering along the luminal surface. Numbers of inflammatory cells, 
including lymphocytes, mast cells and basophils are also increased in the 
affected epithelial space (54). EoE is characterized by a Th2 response with the 
increase in the expression of IL-4, IL-5 and IL-13 (45). STAT6 mediates the 
expression of eotaxin-3/CCL26 (55, 53, 56) and hence eosinophil accumulation 
in EoE (57–59). Esophageal biopsies from children with EoE have increased 
expression of CCL26 (47). Genome wide association studies have reported three 
genes – TSLP, CCL26 and Calpain-14 as being altered in EoE (54). Th2 
cytokines IL-5 and IL-13 downregulate the expression of desmoglein-1 (DSG1) 
and genes of the epidermal differentiation complex (EDC) like filaggrin (FLG) (60, 
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61) and impair barrier function. Altered esophageal barrier function could thus 
lead to enhanced antigen presentation and greater eosinophil recruitment.  
 
Skin Physiology  
The skin is the largest organ of the body with varied and important functions. It is 
composed of two main layers, the epidermis (uppermost layer) and the dermis, 
with the subcutaneous layer beneath the dermis (Figure 3A). Thickness of the 
skin varies depending on the area of the body and function and can range from 
0.5mm in the eyelids to 3-4mm in the soles of the feet with an average thickness 
of 1-2mm (62). 
 
 
 
Figure 3. Skin Physiology. (A) Cross section of skin tissue showing structure of 
skin (B) Cross section of the epidermis showing different layers of keratinocytes.  
Modified from McLafferty et al. Nurs. Stand. 2012. 
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The epidermis is composed of many layers of stratified keratinized squamous 
epithelium. The function of the epidermis is mainly to guard against infection, to 
prevent dehydration, and for re-epithelialization after wounding (63). Epidermis 
mainly consists of keratinocytes (90%), Langerhans cells, melanocytes and 
merkel cells (sensory cells). The epidermis has 4 distinct layers based on the 
stage of differentiation stratum basale, stratum spinousum, startum granulosum 
and startum corneum (Figure 3B).  
 
 
 
Figure 4. Terminal differentiation of keratinocytes. Modified from Candi E et 
al. Nat Rev Mol Cell Biol. 2005. 
 
Basal layer (Stratum basale or Stratum germinativum) is one cell layer thick, and 
consists of proliferating cells that constantly divide to renew the basal layer. 
Basal keratinocytes express keratins 5 and 14 (K5 and K14), commit to 
differentiation by exiting the cell cycle and migrate upwards. Upon cell division, 
the daughter cell migrates up through the many layers to the surface of the 
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epidermis where they get sloughed from the skin surface. As the skin is of varied 
thickness based on its location in the body, this process takes approximately 28 
days (62). The cells of the stratum basale migrate upwards and form the cells of 
the Stratum spinosum which is 5 - 12 cells thick (62). As the cells exit the basal 
layer and form the spinous layer, they switch the expression of keratin from K14 
and K5 to K1 and K10 (64, 65), a sign that the cell has committed to terminal 
differentiation. The cells join together via desmosomes and cytoskeleton made of 
K1/K10 filament bundles that connect to the desmosomes forming a scaffold. 
Proteins like involucrin (IVL) and loricrin (LOR) are deposited on this scaffold to 
increase mechanical strength and resistance needed for the cornified envelope 
(CE) (66). As the cells move towards the surface, they become longer and form 
horizontally flattened cells of the stratum granulosum. The differentiation into the 
granular layer is associated with a decrease in the expression of K1 and K10 
(66), increase of calcium and synthesis of keratohyalin granules (63, 66). 
Keratohyalin granules are made up of profilaggrin (along with loricrin in murine 
epidermis), which when cleaved forms filaggrin (FLG) peptides that bind to 
keratin with small proline-rich proteins (SPRRs) and LOR on the inside of the CE 
forming tight bundles that are cross-linked by transglutaminase1 (TG1) (Figure 4) 
(64, 66). Lamellar granules called Odland’s bodies are seen in the granular cells. 
They contain lipids like ceramides that are secreted in to the intercellular space 
and play an important role in barrier function (62). By this time, the cells have lost 
their nuclei and cytoplasmic organelles, FLG is further processed into amino 
acids, forming the mature cornified envelope. Cornified envelope (CE) is an 
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insoluble structure of 5-20 nm thick, the proteins are cross-linked by 
transglutaminases that hold the keratin macrofibrils (63, 66). This layer of dead 
cells forms a protective barrier and is continuously sloughed from the surface and 
replenished by cells from the inner layers that move outwards.  
 
Apart from keratinocytes, the epidermis also contains immune cells like the 
Langerhans cells and dendritic epidermal T cells (DETCs). CD8+ T cells are 
usually found in the startum basale and stratum spinosum. In contrast, the 
dermis contains many specialized immune cells like dendritic cells, CD4+ T cells, 
γδ T cells, NKT cells, macrophages and mast cells. Keratinocytes are also a 
main source of antimicrobial peptides like β-defensins and cathelicidins (67, 68).  
Genes that encode for major proteins of the late epidermal differentiation are 
located in a region on human chromosome 1q21; known as the Epidermal 
Differentiation Complex (EDC) (66). EDC contains three families of genes – (a) 
the late cornified envelope proteins that include IVL, LOR (b) calcium binding 
proteins (S100 proteins) and (c) fused gene proteins that include FLG, FLG-2 
and HRNR (66).  
 
The skin barrier maintenance genes that we look at in this dissertation that are 
altered during allergic inflammation include the following: FLG is synthesized as 
profilaggrin consisting of 10-12 tandem repeats of filaggrin peptide. FLG peptides 
are further broken down into hydrophilic amino acids or amino acid by-products 
that maintain the pH levels of the skin. In the absence of FLG, the integrity and 
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cohesion of the corneocytes is weakened, making the barrier leaky, allowing for 
the entry of irritants, microorganisms and increasing trans-epidermal water loss 
(TEWL) (63, 66, 69). Involucrin is a minor component of the human cornified 
envelope and is important during the early stages of CE formation by forming a 
protein layer for the attachment of ceramides (64, 66). Loricrin is one of the most 
abundant proteins in the CE, glycine-rich allowing for flexibility and expression is 
induced by calcium in the late granular layers (64,66).  
 
Other proteins that are important for maintaining skin barrier integrity and 
regulated by IL-4 are CA II, CISH, CCL26, HAS3, SERPINB 3/4. Carbonic 
anhydrase II (CA II) is expressed in varied tissues and this enzyme is involved in 
the maintenance of cellular pH, water transport and in ion homeostasis. Studies 
show that CA II expression in regulated by Th2 cytokines (70).  
 
Cytokine inducible SH2 containing protein (CISH) belongs to the SOCS family of 
proteins and is an inhibitor of the JAK/STAT pathway. CISH expression in 
keratinocytes is induced by both IFNγ and IL-4. In allergic inflammation like 
atopic dermatitis, the expression of CISH is increased (71, 72).   
 
Eosinophils are one of the important inflammatory cells that migrate to a tissue 
during allergic inflammation. The chemokine CCL26 or eotaxin-3 is a 
chemoattractant for eosinophils as their receptor CCR3 is preferentially 
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expressed on eosinophils. Th2 cytokines IL-4 and IL-13 induce the expression of 
CCL26 in keratinocytes (55). 
  
Hyaluronan synthase 3 (HAS3) is responsible for the synthesis of hyaluronic acid 
that is abundant in the dermis and epidermis (73). Hyaluronic acid is expressed 
both in the spinous layer and in the stratum corneum.  Hyaluronic acid and HAS3 
are involved in proliferation, differentiation and migration of keratinocytes and in 
maintaining the epidermal barrier. HAS3 is upregulated by proinflammatory 
cytokines IL-4, IL-13 and IFNγ and an increase in HAS3 is observed during 
inflammation along (74) with an increase in hyaluronic acid causing spongiosis 
(75). 
 
SERPINB3/4 are serine protease inhibitors that were first identified to inhibit 
proteases and caspases. SERPINB3/4 have been implicated in allergic disorders 
like asthma and in atopic dermatitis and IL-4 and IL-13 via STAT6 induce their 
expression in bronchial epithelial cells. Serine proteases are critical for epidermal 
barrier homeostasis and elevated levels of SERPINB3/4 are implicated in atopic 
dermatitis and psoriasis (76, 77).  
 
Atopic Dermatitis 
Atopic dermatitis (AD) is a chronic, relapsing inflammatory condition of the skin. 
AD usually presents during early infancy and childhood but can persist into 
adulthood or start during adulthood. The key characteristics of AD include 
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pruritus, scratching and chronic relapsing lesions. AD is characterized by 
increases in total IgE levels, infiltration of mast cells and eosinophils, decreases 
in anti-microbial peptides and increased expression of Th2 cytokines (78). Many 
researchers favor to differentiate AD into extrinsic and intrinsic types, where 
extrinsic AD patients show high total serum IgE levels that are specific to 
environmental or food allergens and intrinsic AD patients show normal IgE levels 
(79). The cause of AD is still unknown though genetic factors play an important 
role. Mutations in the epidermal differentiation complex (EDC, important during 
terminal differentiation of keratinocytes) gene, filaggrin (FLG) can cause skin 
barrier impairment (80, 81). Loss-of-function mutation in FLG along with copy 
number variation is a strong predisposing factor for atopic dermatitis and this 
mutation is carried by approximately 9% of the European population (80, 82, 83). 
Flg mutant mice (flaky tail mice - Ft) carry mutations similar to mutations seen in 
AD patients and these mice have increased propensity to develop spontaneous 
AD-like skin lesions (84–86). 
 
STAT6 and Th2 cytokines, IL-4 and IL-13 decrease the expression of EDC genes 
filaggrin (FLG), loricrin (LOR) and involucrin (IVL) in human skin biopsies and in 
differentiated primary human keratinocytes (87, 88). IL-4 and IL-13 are elevated 
in the skin of patients with AD and either cytokine can lead to decreased 
expression of antimicrobial genes like human β defensins (HBD)-2 and 3 (78, 
89). Polymorphisms in genes encoding the cytokines IL-4 and IL-13 have shown 
association with AD. Polymorphisms in the promoter of IL-4 in an Egyptian 
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population and Czech population (90, 91) and polymorphisms in IL-13 gene in 
Caucasian population (92) and Japanese populations (93) show association with 
AD.  Several polymorphisms in IL-4Rα have been found to be associated with AD 
(94–96). SNPs in Stat6 gene also show association with allergic disease 
including AD (90, 97). 
 
Atopy is generally associated with increased activation of STAT6, hence a 
transgenic mouse model with constitutively phosphorylated STAT6 in T cells was 
generated to define a direct role for STAT6 in allergic inflammation (98). STAT6 
transgenic mice, termed STAT6VT express a constitutively active form of STAT6 
in T cells generated by mutating V-547 and T-548 to alanine in the SH2 domain 
resulting in constitutive phosphorylation of tyrosine residue, Y-641, independent 
of IL-4 stimulation (98). STAT6VT mice have increased Th2 cell differentiation 
and increased serum IgE levels (98). STAT6VT mice develop spontaneous 
allergic inflammation in the tissue around the eye, in the lung and in the skin (99-
101). Slower recovery of skin injury caused by treatment with retinoic acid, 
detergent and vitamin D analogs were observed in STAT6VT mice (101-103).  
STAT6VT mice are also more susceptible to infections (104). STAT6VT mice 
skin has diminished expression of epidermal differentiation complex (EDC) genes 
and decreased barrier function (100). The absence of endogenous IL-4 protects 
the STAT6VT transgenic mice from allergic inflammation (99, 100). Many murine 
models of AD exist that require either gene overexpression in the skin, like 
transgenic mice expressing IL-4 or IL-13 in the epidermis of the skin (105, 106) 
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or experimental skin exposure to irritants. However, the STAT6VT model of AD 
primes a Th2 immune response that results in the spontaneous development of 
allergic skin inflammation under specific-pathogen free (SPF) conditions, thus 
making it an ideal model to study AD.  
 
Atopic diseases start early in life and have a typical progression. This 
progression of atopic disorders from atopic dermatitis in infants to allergic rhinitis 
and asthma in children is referred to as atopic march. Atopy is considered to be 
critical in linking AD, allergic rhinitis and asthma. Genetic and environmental 
factors strongly influence disease development. Once diagnosed, children may 
develop a sequence of atopic diseases at certain ages. Studies have identified 
PARP14 to promote AAD in a murine model. The role of PARP14 in other atopic 
diseases has not yet been determined. Thus, the studies in this dissertation are 
focused on gaining a better understanding of the function of PARP14 in other 
allergic diseases such as atopic dermatitis and eosinophilic esophagitis. 
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Research goals 
Poly ADP-ribose polymerase 14 is one of a family of 17 PARPs with mono-ADP 
ribosyl transferase activity. PARP14 was initially identified as a transcriptional co-
activator, where in the presence of IL-4 the catalytic activity associated with 
PARP14 facilitates the binding of STAT6 to the promoter and aids in 
transcription. PARP14 and its catalytic activity promote the differentiation of T 
cells into Th2 cells by facilitating in the binding of STAT6 to Gata3 promoter. 
Studies on PARP14 deficient mice show that, allergen induced airway 
inflammation is attenuated and administration of a PARP inhibitor alleviated 
disease. The goal of this research is to investigate the role and function of 
PARP14 in allergic inflammation of the esophagus and the skin. We aim to 
determine the function of PARP14 in regulating the expression of eotaxin-3 and 
hence in the pathogenesis of eosinophilic esophagitis. Next, we studied the role 
of PARP14 in allergic skin inflammation using a model of spontaneous 
inflammation (Stat6VT mice). Together, our studies would further our 
understanding of the function of PARP14 in the pathogenesis of allergic 
inflammation.  
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MATERIALS AND METHODS 
 
Patient Population 
EoE biopsies (n=16) were obtained from children who were diagnosed with EoE 
(>15 eosinophils per high power field (hpf)). Biopsies from control subjects were 
obtained from children undergoing endoscopy but with no disease on 
pathological examination with 0 eosinophils per hpf (n=17). This study was 
approved by the Institutional Review Board of Indiana University, and informed 
consent for the participation in this study was obtained from parents of children 
enrolled in the study. We would like to thank Dr. Sandeep Gupta, Indiana 
University School of Medicine for the patient samples. 
 
RNA isolation from Esophageal Biopsy and Gene Expression 
RNA was isolated from esophageal biopsies using RNeasy fibrous tissue mini kit 
(Qiagen) according to manufacturer’s protocol. RNA was reverse transcribed to 
make cDNA according to the manufacturer’s instruction. Quantitative PCR 
reactions were setup by adding cDNA, Taqman primers (ThermoFisher 
Scientific), Taqman Fast Universal Master Mix (Applied Biosystems) and DEPC 
to a final volume of 10µl in MicroAmp Fast Optical 96-well plates (Applied 
Biosystems). Quantitative PCR was performed on duplicate samples using 7500 
Fast Real-Time PCR system. Samples were normalized and gene expression of 
the indicated genes was assessed using quantitative PCR. Samples were 
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normalized to β2- microglobulin mRNA and relative expression was calculated 
using the change-in-threshold method.  
 
Esophageal epithelial cell culture  
TE-7 and TE-1 esophageal epithelial cells, derived from human esophageal 
squamous cell carcinoma, obtained from Drs. Pierre Hainaut and Jean-Yves 
Scoazec, were cultured in RPMI-1640 medium (supplemented with 10% (vol/vol) 
FBS (Atlanta Biologicals), 1 mM glutamine (Lonza-BioWhittaker), 100 U/ml 
penicillin/streptomycin (Lonza-BioWhittaker), 10 mM HEPES, pH 7.3 (Lonza-
BioWhittaker), 1 mM sodium pyruvate (Lonza-BioWhittaker) and 50 µM 2-
mercaptoehtanol). Cells were incubated in the presence or in the absence of 2.5 
ng/ml IL-4 or 20 ng/ml IL-13. The cells were then treated with 25 µM PARP 
inhibitor, PJ34.  
 
Luciferase assay 
TE-7 esophageal epithelial cells were transfected using Transfectin (BioRad) with 
a CCL26 luciferase reporter or a reporter with a mutated STAT6 binding site and 
control, STAT6 or PARP14 expressing plasmids. Twenty-four hours later cells 
were cultured in fresh RPMI media and incubated in the presence of 25 ng/ml of 
IL-4 or 25 ng/ml of IL-13 for 24 hours. The cells were then trypsinized and 
washed in PBS containing 10% FBS.  GFP expression from control samples was 
assessed using flow cytometry. Luciferase substrate (Promega) was added to 
test samples, before luciferase activity was assessed.  
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Mice  
C57BL/6 (Wild-type) mice were purchased from Harlan Biosciences. Parp14-/- 
mice on C57BL/6 background were generated by an insertion into 5’ end of the 
first exon of PARP14 locus (44). Stat6VT transgenic mice were previously 
described (98). Transgene positive cofounders were (CD2:Stat6VT (78) line) 
carrying human Stat6 with V547 and T548 mutated to alanine under the control 
of CD2 locus control region (restricting expression to lymphoid populations) and 
backcrossed to C57BL/6 mice. Stat6VT is constitutively phosphorylated on the 
critical tyrosine, Y-641. This phosphorylation is important for the dimerization of 
Stat6VT and its ability to activate transcription. Parp14-/- mice were mated to 
Stat6VT mice to generate Parp14-/- deficient transgene positive mice. Mice were 
kept in specific pathogen-free condition and all studies were approved by Indiana 
University Institutional Animal Care and Use Committee.  
 
CD4 T cell differentiation 
Naïve CD4+ CD62L+ T cells were purified from spleens using magnetic isolation 
(Miltenyi Biotec). Naïve cells were cultured in complete RPMI medium 
(supplemented with 10% (vol/vol) FBS (Atlanta Biologicals), 1 mM glutamine 
(Lonza-BioWhittaker), 100 U/ml Penicillin (Lonza-BioWhittaker), 100 µg/ml 
Streptomycin (Lonza-BioWhittaker), 10 mM HEPES, pH7.3 (Lonza-BioWhittaker), 
1 mM Sodium pyruvate (Lonza-BioWhittaker), 50 µM 2-mercaptoehtanol). Naïve 
cells were activated with plate bound anti-CD3 (2 µg/ml – 2C11) and soluble anti-
CD28 (0.5 µg/ml). Cells were polarized to generate Th0 (anti-IFNγ/XMG -10 
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µg/ml, anti-IL-4/11B11 – 10 µg/ml, hIL-2 -50 U/ml) and Th2 (IL4 -10 ng/ml, anti-
IFNγ/XMG – 10 µg/ml) cells. Cells were expanded after 3 days with media alone. 
After five days, cells in culture were harvested for analysis.  
 
Surface and Intracellular staining 
For splenocytes, cells were stimulated with PMA and Ionomycin or anti-CD3 (2 
µg/ml) for 5 hours at 37°C, with the addition of 3 µM monensin during the last 4 
hours of stimulation. After 5 hours, the cells were collected and stained with a 
fixable viability dye dissolved in PBS (eBioscience) along with surface markers 
for CD4 for 20 min at 4°C. The cells were then fixed with 4% formaldehyde for 10 
min at RT, permeabilized (BD Biosciences) and with fluorochrome conjugated 
antibodies for IL-4, IL-13, IFNγ and IL-17A.  
 
For phospho-STAT6 staining, differentiated Th0 and Th2 cells were fixed with the 
viability dye (eBioscience) and fixed with 4% formaldehyde at RT for 10 min. 
Cells are permeabilized in 100% methanol overnight at 4°C and stained the next 
day using fluorochrome conjugated antibody for phospho-STAT6 for 1 hour at 
RT. Cells were analyzed by flow cytometry using Attune Flow Cytometer 
(ThermoFisher Scientific) and results were analyzed using FlowJo. 
 
ELISA 
To obtain sera, blood obtained by cardiac puncture from mice was centrifuged at 
12,000 rpm for 15 min at 4°C and sera collected was used for ELISA. To 
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generate cell-free supernatants, splenocytes were stimulated with plate-bound 
anti-CD3 (4 µg/ml) for 72 hours at 37°C and cell free supernatants were 
collected. 96-well Nunc MaxiSorp plates were coated with capture antibodies (2 
µg/ml; BD Biosciences) dissolved in PBS or 0.1 M NaHCo3 buffer (pH 9) 
overnight at 4°C. Plates were then washed three times with ELISA wash buffer 
(0.1% Tween-20 in PBS) and blocked with ELISA blocking buffer (2% BSA, 
0.01% NaN3 in PBS) for 1 hour at room temperature. After washing the plates, 
diluted standards and samples (sera or cell free supernatants) were added and 
incubated at 4°C overnight. The wells were washed four times with ELISA wash 
buffer and biotinylated antibody (1 µg/ml; BD Biosciences) dissolved in ELISA 
blocking buffer were added (2 µg/ml, BD Biosciences) and the plates were 
incubated at 4°C overnight. Wells were washed four times with the wash buffer 
and incubated with avidin-alkaline phosphatase (1:2000; Sigma) dissolved in 
ELISA blocking buffer and incubated for 1 hour at RT. Wells were washed four 
times with wash buffer and phosphatase substrate (4 mg/ml; Sigma) dissolved in 
ELISA substrate buffer (10% diethanolamine, 0.05mM MgCl2, 0.02% NaN3; pH 
9.8) was added. Absorbance was read at 405 nm (Bio-Rad microplate reader 
model 680).   
 
Adoptive transfer 
Splenic CD4+ cells were magnetically sorted (Miltenyi Biotec) from wild-type, 
Stat6VT and Stat6VTxParp14-/- mice. Cells were re-suspended in PBS at a 
concentration of 1.5x106 cells/ml – 3x106 cell/ml and cells were transferred by 
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retro-orbital injections into 8-10 week-old Rag1-/- mice. Mice were monitored for 
10-20 weeks for the development of skin inflammation and spleens and skin 
were harvested.  
 
MEASI Scoring 
Stat6VT and Stat6VTxParp14-/- mice were scored using Mouse Eczema Area 
Severity Index (MEASI) scoring system. EASI (Eczema area severity index) 
method of scoring skin lesions in humans has been modified and adapted to 
mice and referred to as MEASI. Here the skin lesions in different mouse body 
areas (Head, trunk, tail) are given a score from 0 – 3 (nil, mild, moderate, severe 
respectively) for erythema, excoriation, lichenification and infiltration.  
Stat6VT and Stat6VTxParp14-/- mice with blepharitis and a MEASI score <1 
were characterized as having mild disease. Mice with skin lesions and a MEASI 
score >1 were characterized as having severe disease.  
 
Histological examination of skin sections 
Skin tissues were fixed in neutral buffered formalin. Paraffin embedded tissue 
sections were stained with hematoxylin and eosin to evaluate the infiltration of 
inflammatory cells by light microscopy. Slides were scored using a semi-
quantitative scoring scale: 0= no inflammation, 1= 5-25%, 2= 26-50%, 3= 51-70% 
4 = 71-90% 5= 91-100% infiltration of cells.   
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Keratinocyte cell culture 
Primary human keratinocytes (HK) were isolated from excised foreskin tissue as 
previously described (107) and washed with antibiotics. The tissue was minced 
and the individual cells were released from the tissue using trypsin digestion. 
Keratinocytes and fibroblasts were separated by differential resistance to 
treatment with EDTA. Isolated HK were grown in EpiLife Complete media 
(Cascade Biologics) with human keratinocyte growth supplement (containing 5 
µg/ml insulin; Cascade Biologics) and 1000 U penicillin–streptomycin (Roche, 
Indianapolis, IN, USA). To stimulate keratinocyte differentiation, HK were treated 
with 2 mM of CaCl2 every other day and stimulated with recombinant human IL-4 
(R&D Systems) as indicated. 
 
Gene expression analysis (quantitative RT-PCR) 
RNA was isolated using TRIzol (Ambion Life Technologies) and reverse 
transcribed to make cDNA using First-strand cloned AMV kit (Invitrogen). 
Quantitative PCR reactions were setup by adding cDNA, primers (Applied 
Biosystems), Taqman Fast Universal Master Mix (Applied Biosystems) and 
DEPC to a final volume of 10 µl in MicroAmp Fast Optical 96-well plates (Applied 
Biosystems). Quantitative PCR was performed on duplicate samples using 7500 
Fast Real-Time PCR system. Samples were normalized and gene expression of 
the indicated genes was assessed using quantitative PCR. Samples were 
normalized to β2 microglobulin mRNA and relative expression was calculated 
using the change-in-threshold method.  
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Cell isolation from the skin 
Ear skin from mice were split and placed in a 6-well dish containing 1.5 ml RPMI 
with Liberase (2 mg/ml; Roche) with the dermis facing down. Skin samples were 
incubated at 37°C, 5% CO2 for 1.5 hours. At the end of 1.5 hours, liberase was 
inactivated with RPMI containing FBS and the samples were disrupted to 
dissociate the cells using gentleMACS Dissociator (Miltenyi Biotec). Cells were 
stained for specific surface markers based on the cell type. Basophils – CD19-
CD117-NK1.1-CD3-CD11c-CD49b+FcεRIa+, Eosniophils – CD11c-CD11b-Gr1- 
SiglecF+, Neutrophils – CD11b+Gr1+, Mast cells – CD3-CD117+FcεRIa+, T-cells - 
CD3+CD4+ or CD3+CD8+ 
 
Retroviral transduction 
Retroviral expression vector expressing eGFP (MIEG), or vectors that express 
STAT6VT along with eGFP have been previously described (102). Two days 
after naïve T cells were cultured under Th0 or Th2 conditions, the cells were 
transduced with retroviral supernatant for, MIEG control vector or STAT6VT-
MIEG in the presence of polybrene (8 µg/ml) and IL-2. Cells were expanded on 
day 3 of culture and harvested on day 5. After 5 days, cells were stained with 
fluorochrome conjugated IL-4, IL-13, phospho-STAT6 analysis was carried out by 
flow cytometry for cells that were positive for GFP.  
 
 
 
	 41 
Epicutaneous sensitization 
Induction of skin inflammation via epicutaneous sensitization has been described 
before (108). 8-10 week-old mice were sensitized by i.p. injection of Ova (20 µg; 
Sigma) adsorbed in alum (2 mg; Sigma) on day 0 and 7. On day 14, backs of 
anesthetized mice were then shaven and tape-stripped 6 times with type IV 
transparent dressing (Blenderm; 3M). 100 µg of Ova in 100 µl PBS or 100 µl PBS 
was applied on a patch of sterile gauze (1x1 cm), which was secured to the skin 
with a transparent bio-occlusive dressing (Bioclusive Mini; Systagenix) and 
dressing tape (Mediapore tape; 3M). Mice were challenged for 2 days with an 
interval of 2 days for a total five 2-day exposures. Hence, mice were challenged 
for 2 days, from days 14-30. Mice were sacrificed 4 days after the last challenge 
(on day 35) and spleens, lymph nodes and serum were harvested.  Skin was 
harvested for histology.  
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RESULTS 
 
Part I – PARP14 and eosinophilic esophagitis 
 
Macro-PARP gene expression in children with eosinophilic esophagitis (EoE) 
PARP14 is known to function as a transcriptional co-factor for STAT6 and in a 
model of allergic airway inflammation, mice deficient in PARP14 had increased 
lung function, diminished cellular infiltration and decreased production of Th2 
cytokines compared to control mice (37). However, the requirement and function 
of PARP14 in STAT6 dependent gene expression in non-lymphoid cells and in 
human disease have not yet been assessed. To study this, we obtained 
esophageal biopsy samples from children with EoE and control samples from 
children who did not have EoE but had biopsies for diagnostic purposes (Table 
1). To analyze the gene expression of macro-PARPs, we isolated RNA from 
biopsies, and cDNA was assessed by qPCR. We observed a 5.95 fold average 
increase in PARP14 expression and a 3.1 fold average increase in PARP1 
expression, and a decrease in PARP15 expression in EoE biopsies compared to 
controls (Figure 5). In contrast, we did not observe a significant difference in the 
expression of PARP9. A similar increase (4.5 fold) in PARP14 expression was 
observed in EoE biopsies from Cincinnati Children’s Hospital Medical Center 
through high-throughput RNA sequencing, and this population had more severe 
inflammation compared to the IU population.  
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Table 1 – Patient Demographics 
 
IU population 
Control EoE 
Number 17 16 
Age - Mean (Range) 8.5 (1.5 - 17.3) 10.7 (2.2 - 17.2) 
Eos/HPF 0 46.4 ± 7.6 
% Male 50 53 
% on PPI 23.5 6.3 
% on H2 Blocker 11.8 0 
% on Corticosteroid 0 25 
% Dicyclomine 5.9 6.3 
% Metoclopromide 5.9 0 
% PPI & H2 Blocker 5.9 0 
% PPI & Corticosteroid 0 0 
% PPI & Dicyclomine 5.9 0 
% PPI & Metoclopromide 5.9 0 
% H2 Blocker & Metoclopromide 5.9 0 
 
PPI – proton pump inhibitor, are potent inhibitors of H+, K+ ATPase and used to 
treat acid reflux  
H2 blockers – prevent histamine from binding to its H2 receptors, thus resulting 
in less acid production 
Corticosteroid – widely used to reduce inflammation  
Dicyclomine – relaxes smooth muscle of esophagus 
Metoclopromide – to treat heartburn  
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Figure 5. Macro-PARP expression in EoE biopsies. RNA was isolated from 
control and EoE biopsies, cDNA was synthesized and expression of the indicated 
macroPARPs was measured by RT-PCR. Data represented as percent β-actin 
control. Statistical significance was determined using ANOVA. 
 
Correlation of PARP14 and CCL26 expression  
The chemokine CCL26 is an important component of the pathology of EoE. Gene 
expression of CCL26 is increased in EoE patient biopsies with a strong positive 
correlation with eosinophil counts in patient biopsies (45, 46). Single nucleotide 
polymorphisms in CCL26 gene are also associated with increased disease 
incidence (45).  Additionally, STAT6 regulates CCL26 expression in esophageal 
epithelial cells (109). Hence, to determine if PARP14 expression correlated with 
CCL26 expression, we tested the association of these 2 genes in EoE patient 
P = 0.01 P = 0.08 
P = 0.02 P = 0.01 
0.279 0.864 
0.273 0.426 
0.241 
1.435 0.047 
0.004 
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biopsy samples and observed a strong correlation with a correlation coefficient of 
0.81 (Figure 6A). In contrast, we did not observe a strong correlation between 
PARP1 and CCL26 (R = 0.30 and P = 0.27) (Figure 6B). We also observe 
significant heterogeneity in the expression of PARP14 in biopsy samples, with 
some overlap with control biopsies. Thus, we observed a positive correlation 
between PARP14 and CCL26 expression.  
 
 
 
Figure 6. Correlation of PARP14 and CCL26 expression. The mRNA 
expression of CCL26 was graphed against PARP14 (A) and PARP1 (B) 
expression. Significance was determined using ANOVA.  
 
 
Role of PARP14 in CCL26 expression 
As our results suggested a relationship between PARP14 and CCL26, we tested 
the ability of PARP14 to regulate CCL26 directly. To test this, the esophageal 
epithelial cell line TE-7 was transfected with a CCL26 luciferase reporter vector 
along with plasmids encoding STAT6 and/or PARP14 and incubated with STAT6 
activating cytokines IL-4 or IL-13. Consistent with our previous results, 
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transfection of STAT6 expressing plasmids increased cytokine induced CCL26 
reporter activity (Figure 7A). Moreover, transfection of PARP14 expressing 
plasmid alone increased both basal and cytokine induced CCL26 reporter activity 
(Figure 7A). Furthermore, we observed that co-transfection of STAT6 and 
PARP14 expressing plasmids significantly increased CCL26 reporter activity 
compared to cells transfected with STAT6 alone (Figure 7A). This effect was not 
observed when cells were transfected with STAT6 expressing plasmid along with 
a CCL26 luciferase reporter that had a mutation in the STAT6 binding site 
(Figure 7A). Suggesting that the effects of PARP14 were completely dependent 
on STAT6 binding. These results suggest that PARP14 could potentially 
modulate CCL26 expression. 
 
To study this further, mRNA expression of CCL26 was assessed in TE-7 cells 
that were incubated with cytokines IL-4 or IL-13 in the presence or the absence 
of a global PARP inhibitor (PJ34) that binds to the PARP catalytic domain and 
inhibits PARP activity. We observed that IL-4 and IL-13 increased CCL26 mRNA 
expression. Incubation with PARP inhibitor PJ34 attenuated the induction that 
was observed with either cytokine (Figure 7B). Similar results were observed 
when TE-1 esophageal epithelial cells were used (Figure 7C). Thus, PARP14 
along with its enzymatic activity contributes to the regulation of CCL26 in 
esophageal cells.  
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B                                                                   C 
                          
 
 
Figure 7.  PARP14 activates CCL26 gene expression.  (A) CCL26 promoter 
reporter activity with co-transfection of STAT6 and/or PARP-14 expressing 
plasmids into TE-7 esophageal epithelial cells *p<0.05, **p<0.001, compared to 
transfection with control plasmids. (B) TE-7 esophageal epithelial cells were 
cultured with IL-4/IL-13 and PARP inhibitor, PJ34. RNA was isolated and CCL26 
gene expression was assessed by RT-PCR. Results are an average of at least 3 
experiments. *p<0.05, **p<0.001. (C) CCL26 expression in cytokine stimulated 
TE-1 esophageal cells incubated with PARP inhibitor, PJ34 (n=1).    
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Part II – PARP14 and allergic skin inflammation 
 
Expression of Stat6VT in T cells of PARP14 deficient mice alters lymphocyte 
homeostasis 
As PARP14 has been known to enhance STAT6-dependent transcription and 
Parp14-/- mice have markedly reduced allergen-induced airway disease (37), we 
wanted to determine the role of PARP14 in STAT6 mediated skin inflammation. 
To study the role of PARP14 in allergic skin inflammation we mated Stat6VT 
mice with Parp14-/- mice to generate Stat6VT transgenic mice (Stat6VTxParp14-
/-). As Stat6VT mice have altered lymphocyte homeostasis and the lymphocyte 
populations are normal in Parp14-/- mice, we wanted to determine if the absence 
of PARP14 had effects on lymphocyte populations in Stat6VTxParp14-/- mice. 
We isolated spleens from wild-type, Parp14-/-, Stat6VT, Stat6VTxParp14-/- mice 
and analyzed their lymphocyte populations by flow cytometry. Stat6VT mice have 
decreased percentage of splenic CD4+ cells compared to wild-type mice (99). 
We observed decreases in the frequency of CD4+ cells in the spleen of both 
STAT6VT and STAT6VTxParp14-/- mice compared to wild-type mice (Figure 
8A). Though the frequencies of CD4+ cells are similar in STAT6VT and 
STAT6VTxParp14-/- mice, the number of CD4+ cells in Stat6VTxParp14-/- mice 
is significantly lower compared to Stat6VT mice (Figure 8B). CD4+ T cells from 
Stat6VT mice have increased amounts of Th2 cytokines IL-4, IL-5 and IL-13 (99). 
To investigate cytokine expression, intracellular cytokine staining of splenocytes 
from wild-type, Parp14-/-, Stat6VT and Stat6VTxParp14-/- mice were performed. 
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ICS showed that CD4+ cells from Stat6VTxParp14-/- have lower percentage of 
IL-4 and IL-13 producing cells but a higher frequency of IL17A producing cells 
compared to Stat6VT CD4+ cells (Figure 8C). To further understand the effect of 
Stat6VT on PARP14 deficient T cells, splenocytes from wild-type, Parp14-/-, 
Stat6VT and Stat6VTxParp14-/- mice were MACS enriched for CD4+ T cells and 
re-stimulated with anti-CD3 for 72 hours and cytokines measured by ELISA. 
Stat6VTxParp14-/- T cells secreted significantly lower amounts of IL-4 and IFNγ 
compared to Stat6VT cells with a decrease in the production of IL-13 (Figure 8D). 
The amount of IL-17A produced by Stat6VTxParp14-/- T cells was significantly 
increased compared to Stat6VT T cells (Figure 8D).  
 
Stat6VT mice have an expanded B cell populations compared to wild-type mice. 
To analyze the B cell population in Stat6VTxParp14-/- mice, we isolated spleens 
from wild-type, Parp14-/-, Stat6VT and Stat6VTxParp14-/- mice and analyzed the 
B cell population by flow cytometry. We observed similar percentages of CD19+ 
cells in Stat6VT and Stat6VTxParp14-/- mice (Figure 8E), while the total number 
of CD19+ cells in Stat6VTxParp14-/- mice was significantly reduced compared to 
STAT6VT mice (Figure 8F).  
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Figure 8. Altered lymphocyte homeostasis in PARP14 deficient Stat6VT 
mice. (A) Splenocytes from age matched wild-type, Parp14-/-, Stat6VT and 
Stat6VTxParp14-/- mice were isolated and percentage of CD4+ T cells 
population was determined by flow cytometry (B) Cell numbers of CD4+ T cells in 
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the spleen of the indicated populations were determined (C) Splenocytes isolated 
from the indicated mice were restimulated with PMA/Ionomycin and stained for 
cytokines produced followed by flow cytometry analysis. (D) MACS sorted CD4+ 
T cells from the spleens of indicated mice were stimulated with plate bound anti-
CD3 for 72 hours, the cell free supernatants were collected and cytokines 
produced were measured by ELISA. (E) Splenocytes isolated from the indicated 
mice were stained with antibody to CD19 and the percentage of CD19+ cells was 
determined by flow cytometry (F) Cell numbers of CD19+ cells in the spleen of 
the indicated populations. Data are mean ± SEM of 3 to 6 mice in each genotype 
(A-C) and mean ± SEM of 6 to 10 mice in each genotype (D). Statistical 
significance was determined by one-way ANOVA (A-C, F) and two-tailed test (D), 
is indicated as follows * p=0.05,  ** p< 0.005, *** p<0.05, # p<0.0001, ## p<0.01 
 
Analysis of cell surface marker expression on B lymphocytes 
To study the expression of genes that are regulated by IL-4 and are Stat6 
dependent, we studied the expression of MHC class II and CD86 on the surface 
of B cells. Percentages of CD19+ MHC-II expressing cells were similar between 
Stat6VT and Stat6VTxParp14-/- mice, but Stat6VTxParp14-/- mice have lower 
number of MHC-II expressing B cells compared to Stat6VT B cells (Figure 9A). 
The frequency and numbers of CD86 expressing B cells were reduced in 
Stat6VTxParp14-/- mice compared to Stat6VT mice (Figure 9B).  
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Figure 9. Cell surface marker expression on B cells. Splenocytes from age 
matched Stat6VT, Stat6VTxParp14-/- mice and their litter-mate controls were 
isolated and stained with antibodies to CD19, MHC-II and CD86. The percentage 
and cell numbers of CD19+ MHC-II+ cells (A) and CD19+ CD86+ cells (B) were 
determined by flow cytometry.  Data are mean ± SEM of 3 to 6 mice in each 
genotype. Statistical significance was determined by one-way ANOVA ** p<0.01 
 
PARP14 deficient Stat6VT mice have increased serum IgE levels 
IL-4 via Stat6 promotes class switching in activated B cells to IgG1 and IgE (110) 
and serum IgE levels are elevated in Stat6VT mice (99). Because 
Stat6VTxParp14-/- mice produce decreased Th2 cytokines compared to Stat6VT 
mice, we wanted to examine serum IgE levels. To test this, we obtained sera 
from 4 month and 12 month old Stat6VT and Stat6VTxParp14-/- mice and 
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analyzed IgE levels by ELISA. Serum IgE levels were significantly elevated in 
both 4 month and 12 month old Stat6VTxParp14-/- transgenic mice compared to 
Stat6VT mice (Figure 10).  
                             
 
Figure 10. Increased serum IgE levels in Stat6VTxParp14-/- mice. Serum 
from Stat6VT and Stat6VTxParp14-/- mice were tested for IgE by ELISA. 
*p<0.01, t-test 
 
CD4+ cells from Stat6VTxParp14-/- mice have decreased Th2 cytokines in the 
absence of inflammation 
Since Stat6VT mice have increased cytokine production, we wanted to test 
whether the effects of PARP14 deficiency were intrinsic to the T cells or an effect 
of inflammation. To examine the effects of PARP14 deficiency in Stat6VT T cells 
in isolation, we transferred CD4+ cells from Stat6VT and Stat6VTxParp14-/- mice 
to Rag1-/- mice. Though we observed an effective transfer of CD4+ cells, we did 
not observe skin inflammation in mice that received either Stat6VT or 
Stat6VTxParp14-/- T cells.  This suggested that T cells are not sufficient to cause 
disease, but also provided the opportunity to observe T cell function in the 
0
100
200
300
400
To
ta
l S
er
um
 Ig
E 
(u
g/
m
l)
Stat6VT
Stat6VTxParp14-/-
Age(months)                4                  12
N      3-4               7-10
* * 
	 54 
absence of inflammation. We observed that 20 weeks post-transfer, Stat6VT 
CD4+ cell recipient mice have a significantly higher frequency of IL-4 and IL-13 
producing cells compared to Stat6VTxParp14-/- recipients (Figure 11A), though 
the frequency of IFNγ was similar between both groups of mice, the frequency of 
IFNγ was increased compared to 10 weeks post transfer (Figure 11B). 
Splenocytes isolated from the Rag1-/- recipient mice were re-stimulated with anti-
CD3 for 72 hours and the levels of secreted cytokines were measured. At 20 
weeks, IL-4 levels were significantly lower in Stat6VTxParp14-/- recipient mice, 
IFNγ levels were also reduced (Figure 11C). The ratio of IFNγ to IL-4 is 
significantly higher in Stat6VTxParp14-/- recipients at 10 weeks compared to 
Stat6VT recipients and further increased at 20 weeks compared to 10-week post-
transfer Stat6VTxParp14-/- recipient cells (Figure 11D). Taken together, these 
data suggest that the decreases of cytokine production caused by PARP14-
deficiency are intrinsic to the T cells. 
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Figure 11. Decreased Th2 cytokines from Stat6VTxParp14-/- CD4+ cells. (A-
B) CD4+ cells from Stat6VT and Stat6VTxParp14-/- mice were adoptively 
transferred to Rag1-/- mice. Splenocytes from the recipients were restimualted 
with PMA/Ionomycin and stained for IL-4, IL-13, IFNγ, IL-17a producing cells and 
analyzed by flow cytometry. (C-D) Cytokines produced from supernatants of anti-
CD3 stimulated splenocytes were analyzed by ELISA. Data from 10-week 
experiment have 5-11 mice per group and 20-week experiment have 6-8 mice 
per group. *p<0.05, **p<0.001 – ANOVA with multiple comparisons, ***p<0.001 – 
t-test.  
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PARP14 deficiency in Stat6VT mice increases disease severity 
As Stat6VTxParp14-/- T cells have altered cytokine production, we next wanted 
to test the ability of PARP14 to modulate allergic skin inflammation. We 
monitored Stat6VT and Stat6VTxParp14-/- mice for the development of AD like 
skin lesions, disease incidence and severity. Stat6VTxParp14-/- mice developed 
severe allergic skin inflammation characterized by erythema, excoriation and 
lichenification (Figure 12A). We observed that a greater percentage of 
Stat6VTxParp14-/- mice developed severe allergic skin inflammation compared 
to Stat6VT mice (Figure 12B). On comparing the percentage of mice that 
required euthanasia or died due to complications associated with severe AD 
lesions using the Kaplan-Meier morbidity analysis, we observed a higher 
percentage of Stat6VTxParp14-/- mice requiring euthanasia because of severe 
disease compared to Stat6VT mice (Figure 12C).   
 
EASI (Eczema Area Severity Index) is a clinical tool for scoring the extent and 
severity of atopic dermatitis lesions. Based on the EASI method of scoring 
human atopic dermatitis lesions, we developed a method to score mouse AD-like 
skin lesions, referred to as MEASI (Mouse Eczema Area Severity Index). AD-like 
skin lesions in mice were scored on characteristics such as erythema, 
excoriation, infiltration and lichenification on a scale of 0-5. Using MEASI, at 5 
months a greater percentage of Stat6VTxParp14-/- mice had severe (>5) MEASI 
score compared to Stat6VT mice (Figure 12D). 
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Figure 12. PARP14 deficiency in Stat6VT mice increases disease severity 
and morbidity. (A) Photographs of wild-type, Parp14-/-, Stat6VT and 
Stat6VTxParp14-/- mice (B) Percent of mice with no disease, mild disease and 
severe disease (AD-like lesions), * p< 0.05, Fisher’s exact test. (C) Percent 
morbidity graphed using Kaplan-Meier analysis, n= 34 ** p< 0.001, Mantel-Cox 
test. (D) Percentage of mice with MEASI score > 5 showing severe disease 
 
Histological analysis of skin inflammation  
Stat6VTxParp14-/- mice had severe inflammation and a higher MEASI score 
compared to Stat6VT mice. To further characterize the histopathology of skin 
inflammation in Stat6VT and Stat6VTxParp14-/- mice, we performed histological 
analysis of skin tissue from wild-type, Stat6VT and Stat6VTxParp14-/- mice. We 
stained formalin fixed skin sections with hematoxylin and eosin and observed 
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increased dermal and epidermal thickening along with an increase in cellular 
infiltration in the skin of both Stat6VT and Stat6VTxParp14-/- mice compared to 
wild-type mice (Figure 13A). Based on the percentage of inflammatory cells, the 
inflammation was scored on a scale of 0-5 (Figure 13B). The hematoxylin and 
eosin staining of the skin tissue sections and the inflammation score suggest 
increased cellular infiltrates in Stat6VTxParp14-/- skin compared to Stat6VT skin.  
 
 
 
Figure 13. Skin histology of Stat6VT and Stat6VTxParp14-/- mice. (A) Skin 
tissue collected from wild-type, Stat6VT and Stat6VTxParp14-/- mice were 
embedded in paraffin and sectioned and stained with heamtoxylin and eosin. 
Images were taken at x100 and x400. (B) Inflammation was scored based on 
several pathophysiological parameters using a semi-quantitative scale of 0-5.  
 
PARP14 deficiency in keratinocytes does not alter epidermal homeostasis 
associated gene expression  
Th2 cytokines are increased in lesional skin and IL-4 is involved in the 
pathogenesis of AD. Skin biopsies from AD patients and primary human 
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keratinocytes differentiated with IL-4 demonstrate decreased expression of 
epidermal differentiation complex genes (87, 88). Based on the effects of 
PARP14 deficiency in allergic skin inflammation and in altering lymphocyte 
homeostasis, we next wanted to determine if the absence of PARP14 or its 
enzymatic activity affect keratinocyte function. To study the function of PARP14 
in keratinocytes, we assessed the expression of IL-4 and STAT6 responsive 
genes that play a role in keratinocyte differentiation and barrier function. Human 
primary keratinocytes were cultured and differentiated in 2 mM calcium chloride 
for 2 days. Keratinocytes were stimulated with recombinant human IL-4 and 
treated with PARP inhibitor PJ34 for 24 hours.  We assessed gene expression by 
qRT-PCR. We observed that on stimulation with IL-4 the expression of STAT6 
dependent genes including CISH, CA2, CCL26, HAS3, SERPINB3 and 
SERPINB4 were increased compared to untreated keratinocytes. On treating 
keratinocytes with the PARP inhibitor PJ34 along with IL-4, we did not observe 
any difference in gene expression compared to cells that were treated with IL-4 
alone (Figure 14). Although PARP14 functions in Stat6-dependent gene 
expression in T cells, B cells, macrophages and esophageal epithelial cells (37, 
44, 47, 111), we observe that in keratinocytes PARP14 enzymatic activity is not 
required for IL-4 responses. Thus, the phenotype observed in Stat6VTxParp14-/- 
mice is not likely to be due to altered function in keratinocytes.  
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Figure 14. Indirect effects of PARP14 on epidermal homeostasis associated 
genes and barrier function.  Human primary keratinocytes were differentiated 
and stimulated with human IL-4 and treated with PARP inhibitor, PJ34. Gene 
expression was measured by RT-PCR. Results are an average of at least 3 
experiments.  
 
Gene expression in the skin  
AD skin biopsies are characterized by over-expression of IL-4 and IL-13 and a 
deficiency in filaggrin gene expression (87). Keratinocytes differentiated in the 
presence of IL-4 and IL-13 also show reduced filaggrin, involucrin and loricrin 
gene expression (87, 88). Skin from Stat6VT mice had decreased expression of 
EDC genes Flg, Ivl, Lor (100). Based on the observation that T cells from 
Stat6VTxParp14-/- mice produce decreased amounts of cytokines IL-4, IL-13 and 
IFNγ compared to Stat6VT T cells but had severe skin inflammation, we tested 
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the expression of EDC genes from lesional and non-leisonal skin tissue. We 
obtained skin biopsies from wild-type, Stat6VT and Stat6VTxParp14-/- mice and 
measured EDC gene expression by qRT-PCR (Figure 15A). Flg expression in 
Stat6VTxParp14-/- lesional skin showed a trend towards an increase in 
expression compared to Stat6VT lesional skin. Similar expression of Ivl and Lor 
were observed in Stat6VT and Stat6VTxParp14-/- lesional skin. 
 
As Stat6VTxParp14-/- mice have severe skin inflammation compared to Stat6VT 
mice, we next wanted to determine the expression of chemokines in the skin. We 
did not observe differences in Ccl11, Ccl22 and Cxcl10 expression between 
Stat6VT and Stat6VTxParp14-/- lesional skin (Figure 15B). Expression of Ccl24 
was higher in non-lesional and lesional Stat6VT skin compared to 
Stat6VTxParp14-/- skin. 
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Figure 15. Expression of EDC genes and cytokines in skin. RNA was 
isolated from wild-type, lesional and non-lesional Stat6VT and Stat6VTxParp14-/- 
skin tissue. Expression of the indicated genes were measured by qRT-PCR, 
samples were normalized to the expression of β2-microglobulin mRNA.  
 
Th2 cytokines are important in altering EDC gene expression; hence we tested 
the expression of cytokines in the skin tissue. The expression of Il4 was higher in 
lesional Stat6VT and Stat6VTxParp14-/- skin compared to wild-type and non-
lesional Stat6VT and Stat6VTxParp14-/- skin. Expression of Il13 was similar 
between wild-type, Stat6VT lesional and non-lesional skin and Stat6VTxParp14-
/- non-lesional skin, though a higher expression was observed in lesional skin 
from Stat6VTxParp14-/- mice (Figure 16A).  
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No differences in the expression of Il17a between the lesional and non-lesional 
skin of Stat6VT and Stat6VTxParp14-/- were observed. The expression of Ifnγ 
showed increases in lesional skin from Stat6VTxParp14-/- mice (Figrure 16A). 
Lesional skin from Stat6VT and Stat6VTxParp14-/- mice displayed similar levels 
of Il12 and Il6 expression, though the expression of Il1b was higher in lesional 
skin compared to non-lesional skin from both Stat6VTand Stat6VTxParp14-/- 
mice (Figure 16B).   
 
To determine T cell recruitment to the skin, we tested the expression of CD3. 
Cd3 expression decreased in non-lesional skin from Stat6VT and 
Stat6VTxParp14-/- mice compared to wild-type skin, however lesional skin from 
Stat6VT and Stat6VTxParp14-/- showed increased Cd3 expression (Figure 16C).  
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Figure 16. Chemokine and cytokine gene expression in skin. RNA was 
isolated from wild-type, lesional and non-lesional Stat6VT and Stat6VTxParp14-/- 
skin tissue. Expression of the indicated chemokine (A) and cytokine (B) genes 
were measured by qRT-PCR, samples were normalized to the expression of β2-
microglobulin mRNA.  
 
Skin infiltrating cells in Stat6VT and Stat6VTxParp14-/- mice 
We observed that Stat6VTxParp14-/- have severe skin inflammation and to 
determine if there was a difference in cellular infiltrate in the skin of Stat6VT 
versus Stat6VTxParp14-/- mice, we wanted to determine the cell types that 
infiltrate the skin of Stat6VT and Stat6VTxParp14-/- mice. To investigate this, we 
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digested the ear skin of wild-type, Parp14-/-, Stat6VT and Stat6VTxParp14-/- 
mice and analyzed the cells infiltrating the skin by flow cytometry. In skin from 
wild-type mice, T cells form 67.3% of the infiltrating cells; mast cells, basophils, 
eosinophils and neutrophils constitute 15.6%, 13.6%, 1.8% and 1.4% of cells 
respectively (Figure 17A). The composition of cells infiltrating the skin of Parp14-
/- mice was similar to wild-type mice, where T cells formed the majority of 
infiltrating cells (68.1%); mast cells, basophils, eosinophils and neutrophils made 
up 14.4%, 14.3%, 2.0% and 1.2% of cells respectively. Skin from Stat6VT mice 
had lower percentage of T cells (35.4%) compared to wild-type or Parp14-/- skin, 
with an increase in the percentage of infiltrating eosinophils and neutrophils 
(15.4% and 18.5% respectively) and a decrease in percentage of basophils 
(7.1%) and mast cells (7.4%) compared to wild-type or Parp14-/- skin. In Stat6VT 
skin we also observed the infiltration of cells (16.1%) that were CD45+ but were 
CD3-, CD19-, NK1.1-, CD117-, CD11b-, CD11c-, CD49b-, FcεRIa-, Gr1- and 
SiglecF- (cells that are not keratinocytes; shown in white in Figure 17A).  
 
Similar to what was observed in Stat6VT skin, Stat6VTxParp14-/- mice had a 
decrease in the percentage of T cells (34.7%) infiltrating the ear skin tissue 
compared to wild-type and Parp14-/- mice. The percentage of eosinophils and 
neutrophils (15.4% and 10.5% respectively) were increased compared to wild-
type and Parp14-/- skin and the percentage of neutrophil decreased compared to 
Stat6VT skin.  The percentage of basophils and mast cells (4.2% and 5.6%) were 
also reduced in comparison to wild-type, Parp14-/- mice and Stat6VT mice. 
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Similar to what was observed in Stat6VT skin, Stat6VTxParp14-/- skin also had 
infiltration of CD45+ cells that are CD3-, CD19-, NK1.1-, CD117-, CD11b-, 
CD11c-, CD49b-, FcεRIα-, Gr1- and SiglecF-. These cells constituted 29.7% of 
the cells infiltrating the skin of Stat6VTxParp14-/- mice, twice as much as that 
was observed in Stat6VT skin (Figure 17A). Though the frequencies of infiltrating 
cells were altered in Stat6VTxParp14-/- skin compared to Stat6VT skin, the total 
cell numbers were reduced compared to Stat6VT skin (Figure 17B).  
 
 
 
Figure 17. Skin infiltrating cells. (A) Ear skin isolated from wild-type, Parp14-/-, 
Stat6VT and Stat6VTxParp14-/- mice were digested in Liberase and the 
dissociated cells were stained with antibodies to infiltrating cells and percentages 
of CD45+ cells infiltrating the skin of indicated mice were determined by flow 
cytometry. (B) Total number of cells infiltrating the ear skin of the indicated 
populations.  
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Stat6VT interaction with Parp14-/- T cells 
Since PARP14 deficient Th2 cells secreted significantly reduced amounts of Th2 
cytokines and PARP14 was required for ambient expression of Gata3 (37), we 
wanted to determine the effect of constitutively active Stat6 (Stat6VT) in PARP14 
deficient T cells. To study how Stat6VT impacts T cells that are deficient in 
PARP14, we retrovirally transduced wild-type and Parp14-/- Th0 and Th2 cells 
with MIEG-Stat6VT or MIEG-GFP (Control) and the resulting GFP+ cells were 
analyzed by flow cytometry. Transduction of Stat6VT retrovirus into either wild-
type or Parp14-/- Th0 or Th2 cells resulted in an increase in the frequency of 
phospho-Stat6 (Figure 18A) and Gata-3 (Figure 18B) and this was similar 
between wild-type and Parp14-/- cells. At the end of 5 days of culture, 
intracellular cytokine staining was performed to study the effect of Stat6VT on 
cytokine expression. In Th0 cells, we observed that transduction of Stat6VT virus 
resulted in an increase in the percentage of IL-4, IL-5 and IL-13 producing 
Parp14-/- cells compared to wild-type cells (Figure 18C). Surprisingly in Th2 
cells, we observed that transducing wild-type or Parp14-/- cells with Stat6VT 
virus reduced the percentage of IL-4 producing cells (Figure 18D). This reduction 
was also observed in the percentage of IL-5 and IL-13 producing cells (Figure 
18D). Our data shows that the presence of Stat6VT in Parp14-/- Th0 culture 
conditions increases Th2 cytokine production, suggesting an altered function of 
PARP14 in the presence of Stat6VT in Th0 cells.  
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Figure 18. Stat6VT interaction with PARP14. (A) Naïve CD4+ T cells from 
Wild-type and Parp14-/- mice were cultured under Th0 and Th2 conditions. On 
day 2 of culture, the cells were infected with either MIEG-GFP (Control) or MIEG-
Stat6VT retrovirus and on day 5, percentage of phospho-Stat6 expressing cells 
were analyzed by flow cytometry. (B) Percentage of Th0 and Th2 cells 
expressing Gata-3. (C, D) On day 5, cells were stimulated with anti-CD3 and 
stained for intracellular cytokine production and analyzed by flow cytometry. 
 
Induced allergen specific skin inflammation 
To investigate the role of PARP14 in a model of allergen specific skin 
inflammation, we performed three different protocols to epicutaneously sensitize 
wild-type and Parp14-/- mice (Figure 19A-C). For all protocols we shaved the 
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backs of mice, tape-stripped the skin and sensitized the mice epicutaneously 
(EC) with Ova. As per protocol in Figure 19C, mice were sensitized on days 0 
and 7 with Ova with the adjuvant alum or PBS (control). A patch of Ova or PBS 
was taped to the backs of mice on days 14, 18, 22, 26 and 30, removed for two 
days in between and mice were euthanized two days after the last Ova or PBS 
patch was removed on day 35. 
 
            
 
Figure 19 (A-C).  Models of epicutaneous sensitization. Schematic diagram 
showing experimental setup of 3 protocols for epicutaneous sensitization.  
 
We observed that the percentage of CD4+IL4+ cells and CD4+IL13+ cells were 
significantly lowered in Ova sensitized Parp14-/- mice and were similar to the 
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PBS treated mice (Figure 20A). Parp14-/- mice sensitized with Ova had lower 
total serum IgE levels compared to wild-type mice, though we do not observe a 
similar decrease in Ova-Specific IgE in Parp14-/- mice (Figure 20B). Th2 
cytokines, IL-4 and IL-13 from the draining lymph nodes were not different 
between wild-type and Parp14-/- Ova sensitized mice (Figure 20C).  Expression 
of EDC genes- Flg, Ivl, Lor and chemokines Ccl11, Ccl22, Ccl24 from the 
epicutaneously sensitized skin were also similar between wild-type and Parp14-/- 
Ova sensitized mice (Figure 20D, E). Though we begin to see an immune 
response upon epicutaneous sensitization, we did not observe robust responses. 
From our studies we observe that upon epicutaneous sensitization, the absence 
of PARP14 does decrease Th2 cytokine production by CD4+ T cells and total 
serum IgE, but does not alter EDC gene expression in the skin.  
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Figure 20. Induced allergen specific skin inflammation.  (A) Wild-type and 
Parp14-/- mice were sensitized with Ova/alum i.p. and challenged epicutaneously 
with Ova for five 2-day challenges. Splenocytes were restimulated with 
PMA/Ionomycin and stained with antibodies to detect cells producing Th2 
cytokines IL-4 and IL-13 and analyzed by flow cytometry. (B) Serum from the 
indicated mice were tested for total IgE and Ova-specific IgE by ELISA (C) Cells 
isolated from the draining lymph nodes were stimulated with anti-CD3 for 72 
hours and the cytokines produced were detected by ELISA (D, E) Epicutaneously 
sensitized skin from the indicated mice were used to generate mRNA and gene 
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expression was measured by RT-PCR. Data are a representative of 3-5 mice per 
group.  
  
	 73 
DISCUSSION 
 
 
 
PARP14 is required to modulate Th2 differentiation through its catalytic activity.  
In a murine model of allergic airway disease, PARP14 is critical to regulate 
disease pathogenesis. Though the function of PARP14 in T cells and in airway 
inflammation has been studied, its function in non-hematopoietic cells and in 
other models of inflammation has not yet been investigated.  Here in part I, we 
identified that PARP14 expression is elevated in EoE biopsies from children. 
CCL26 expression is dramatically increased in EoE biopsies and we demonstrate 
a positive correlation between PARP14 and CCL26 expression. PARP14 and 
PARP catalytic activity also regulate CCL26 expression in esophageal cells. In 
Part II to study allergic skin inflammation, we used Stat6VT model of 
spontaneous allergic inflammation and demonstrate that PARP14 deficiency in 
Stat6VT mice altered cytokine production and Stat6VTxParp14-/- mice 
developed severe allergic skin inflammation. However in keratinocytes, PARP14 
was not required for the induction of IL-4 responsive genes. Adoptive transfer of 
Stat6VTxParp14-/- CD4+ cells established that decreases in cytokine production 
were due to a T cell intrinsic function of PARP14. In addition, an altered cellular 
infiltrate was observed in the skin of Stat6VTxParp14-/- mice compared to 
Stat6VT mice. Together our findings provide insight into the role of PARP14 in 
allergic inflammation, carrying out different functions depending on the target 
organ. 
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PARP14 and Eosinophilic esophagitis 
 
EoE is an emerging chronic allergic inflammatory disorder of the esophagus that 
is characterized by esophageal eosinophilia and symptoms related to 
esophageal dysfunction. There is limited information about EoE disease 
pathogenesis and its treatment options. Early studies have demonstrated that 
esophageal eosinophilia occurs in association with Th2 allergic responses  (112, 
113, 114). IL-5 and IL-13 promote eosinophil infiltration in to the esophagus. A 
genome wide microarray expression analysis of EoE biopsies revealed the 
differential expression of 574 genes, of which eotaxin-3 was the most 
overexpressed gene (45). The human eotaxin-3 promoter carries a STAT6 
consensus binding motif (53). In the current study we focused on identifying the 
function of PARP14 in regulating CCL26 expression in esophageal epithelial 
cells. Prior studies have demonstrated PARP14 functions as a co-activator of 
STAT6 under stimulating conditions in T cells, B-cells and in airway epithelium 
(37, 44). Here we demonstrated the expression of macro-PARPs in esophageal 
biopsy samples from pediatric patients and observed an increase in the 
expression of PARP1 and PARP14. We demonstrated a correlation between the 
expression of PARP14 and CCL26 in patient biopsy samples. Though PARP1 
has not been implicated in EoE, PARP1 has been extensively studied in other 
models of allergic inflammation such as asthma. In asthma, PARP1 deficiency 
decreases cell infiltration into the lung, airway hyperresponsivess and mucous 
secretion (25, 26, 27 & 28). PARP1 deficiency decreases IL-5 production and 
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thus eosinophil infiltration into the lung (24). This suggests that PARP1 could 
also play a role in recruiting eosinophils to esophageal epithelial cells and hence 
in EoE. Though a significant correlation with CCL26 expression was not 
determined, PARP1 could regulate the expression of other eosinophil 
chemoattractants (CCL11, CCL24).  
 
Intestinal epithelial cells stimulated with IL-4 or IL-13 increased the expression of 
eotaxin-3 in a dose dependent manner (53). STAT6 signaling via IL-4/IL-13 was 
sufficient to activate transcription of eotaxin-3 (53). Our studies provide evidence 
for the ability of PARP14 to directly regulate eotaxin-3 expression via STAT6 
pathway in esophageal epithelial cells. Effects of PARP14 were entirely 
dependent on STAT6 binding to eotaxin-3 promoter. Inhibiting PARP activity 
using a global PARP inhibitor (PJ34) decreased the expression of eotaxin-3. 
However, PARP14 could also be expressed by and function in other cells that 
contribute to the pathology of EoE. Mucosal layers of the esophagus and skin 
show similarity and altered expression of epidermal differentiation complex 
(EDC) genes have been observed in EoE and in AD. Filaggrin and involucrin 
expression was downregulated in EoE biopsies and increasing concentrations of 
IL-13 decreased filaggrin and involucrin expression. IL-13 via STAT6 regulates 
the expression of involucrin in TE-7 cells. This suggests that PARP14 could 
regulate the expression of involucrin in esophageal epithelial cells and hence in 
EoE (60).  
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PARP14 and allergic skin inflammation 
 
The function of PARP14 in allergy is emerging, though its role in allergic skin 
inflammation and in keratinocytes is still unclear. In this study we demonstrate 
that decreases in cytokine production by Stat6VTxParp14-/- mice are intrinsically 
due to PARP14 deficiency in T cells. The absence of PARP14 in Stat6VT mice 
escalates the severity of spontaneous allergic skin inflammation. In 
keratinocytes, PARP14 is not required for the induction of IL-4 and Stat6 
responsive genes that are important for maintaining skin barrier function. In 
addition, altered immune responses also resulted in altered cellular infiltrate in 
the skin of Stat6VTxParp14-/- mice compared to skin from Stat6VT mice. 
Together, these data suggest PARP14 deficiency alters immune responses thus 
altering cellular infiltrate in the skin in a model of spontaneous allergic skin 
inflammation. 
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Figure 21. Summary showing the effect of PARP14 deficiency in Stat6VT 
mice and hence in allergic skin inflammation.  
 
Previous studies on Stat6VT mice have demonstrated decreased percentages of 
T cells in the periphery and Stat6VT T cells are predisposed to differentiate into 
Th2 cells (98). In this report, we showed that PARP14 deficiency preserves the 
effects of Stat6VT expression with similar percentages of T cells in Stat6VT and 
Stat6VTxParp14-/- spleens. Though the frequency of T cells was similar, T cell 
numbers were significantly reduced in Stat6VTxParp14-/- mice. T cells from 
Stat6VT mice secreted increased levels of the Th2 cytokines IL-4 and IL-13. We 
demonstrated a decrease in IL-4 and IL-13 production in T cells from 
Stat6VTxParp14-/- mice. This is in agreement with previous studies where 
PARP14 has been shown to affect Th2 differentiation (37). Adoptive transfer of 
CD4+ T cells into Rag1-/- mice resulted in an increased IFNγ/IL-4 ratio. This 
could be attributed to the ability of PARP14 to negatively regulate Stat1 and 
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positively regulate Stat6 expression (42). In vitro, Parp14-/- Th17 cells had 
significantly reduced frequency of IL-17A+ cells and in vivo, in a model of allergic 
airway disease, Parp14-/- mice had decreased numbers of IL-17A producing 
CD4+ cells and reduced concentration of IL-17A from antigen-stimulated 
splenocytes (43). However, in Stat6VTxParp14-/- mice, we observed an overall 
increase in IL-17A-producing CD4+ cells. IL-4 has been shown to suppress IL-23 
and IL-17 (115), suggesting that increase in IL-17A in Stat6VTxParp14-/- T cells 
could be due to decreases in IL-4. Increase in IL-17A could also represent 
increased bacterial infections in the AD-like lesions (116). Studies in AD patients 
revealed a correlation of AD severity with increased IL-17 producing T cells in the 
peripheral blood and in acute lesional skin (117). Adoptive transfer of CD4+ T 
cells into Rag1-/- mice did not result in altered IL-17A levels and these mice did 
not develop skin inflammation, suggesting that elevated IL-17A could cause 
allergic skin inflammation. Thus, IL-17 producing cells may contribute in 
Stat6VTxParp14-/- disease severity.  
 
In the presence of IL-4, PARP14 promotes Stat6 binding to target gene 
promoters in B-cells and potentiates IL-4 induced Stat6 dependent transcription 
(34, 36). Stat6VT mice have an expanded B cell population in the periphery (98). 
This increased B cell population is due to IL-4/Stat6 dependent increase in Bcl-x 
expression (98). Though we observe similar increases in peripheral B cell 
population in Stat6VTxParp14-/- mice, we observed a significant reduction in B 
cell numbers in the spleen compared to Stat6VT mice. PARP14 has been shown 
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to regulate genes that promote B cell survival.  Decreases in the expression of 
anti-apoptotic genes Bcl-x and Mcl-1 in Parp14-/- B cells increases their 
susceptibility to apoptosis (44). Thus, the decrease in B cell numbers in 
Stat6VTxParp14-/- mice could be due to altered expression of B cell survival 
genes. Cell surface markers like MHC Class II and CD86 that are up-regulated 
upon IL-4 stimulation, were elevated in B cells from Stat6VT mice (98). In line 
with reduced IL-4 produced by Stat6VTxParp14-/- T cells, we observed 
decreased number of MHC class II and CD86 positive B cells. Although Th2 
cytokines were reduced in Stat6VTxParp14-/- mice, we observed highly elevated 
serum IgE levels. This could be attributed to altered isotype class switching to 
IgE. As described above, we observed increased levels of IL-17A in 
Stat6VTxParp14-/- mice. It has been reported that IL-17A promotes IgE 
production in human B cells in vitro (118), suggesting a pro-allergic role for IL-
17A.  
 
PARP14 regulates transcriptional function of Stat6 in T cells and B cells (36), 
however in keratinocytes we observe that inhibiting PARP14 using PARP 
inhibitor, PJ34 does not affect IL-4 responsive gene expression. In contrast, in 
esophageal cells we demonstrated PARP14 regulates Stat6 responsive gene 
expression of CCL26 and blocking PARP catalytic activity of PARP14 using PJ34 
decreased CCL26 expression. Though PJ34 is a global PARP inhibitor, previous 
studies in a model of allergic airway disease demonstrate that using PJ34 in 
Parp14-/- mice did not further alleviate disease, suggesting that PARP14 is the 
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major PARP in allergic inflammation (37). Thus, though PARP14 alters IL-4 
responsive gene expression in esophageal cells, in keratinocytes inhibiting 
PARP14 did not alter IL-4 responsive gene expression. This suggests that the 
skin inflammation observed in Stat6VTxParp14-/- mice was not likely due to an 
altered function in keratinocytes.  
 
One of the questions we have tried to address is whether the skin infiltrating cells 
were altered in Stat6VTxParp14-/- mice. We characterized the cells infiltrating 
the skin from Stat6VT and Stat6VTxParp14-/- mice and observed that the largely 
altered cell infiltrate had a decrease in the frequency of neutrophils, basophils 
and mast cells in Stat6VTxParp14-/- skin compared to Stat6VT skin. Although 
there was a decrease in the frequency of mast cells, we observed an increase in 
the absolute number of mast cells in the skin of both Stat6VT and 
Stat6VTxParp14-/- mice (119). Decreased percentages and cell numbers of 
neutrophils in Stat6VTxParp14-/- skin could be attributed to impaired neutrophil 
migration from bone marrow to the periphery as observed in allergic inflammation 
(120, 121). Moreover, we observed the infiltration of hematopoietic cells (CD45+) 
that were negative for CD3, CD19, CD117, NK1.1, CD11c, CD11b, CD49b, GR1, 
FcεRIα and SiglecF in Stat6VT skin. This cell population was further elevated in 
Stat6VTxParp14-/- skin. Looking at other CD45+ cells, studies on leisonal skin of 
transgenic mouse models of AD show an increase in macrophage infiltration 
(122, 123). Other studies in human AD have also shown the involvement of 
macrophages in both acute and chronic lesions. In chronic lesions macrophages 
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participate in skin remodeling and dominate the dermal mononuclear cell infiltrate  
(124, 125). Skin from mast cell deficient Stat6VT mice has shown an increase in 
tissue macrophages (119). Thus, it is possible that CD45+ cells that were 
negative for CD3, CD19, CD117, NK1.1, CD11c, CD11b, CD49b, GR1, FcεRIα 
and SiglecF could be macrophages. Taken together, our data suggests that the 
altered immune response observed in the Stat6VT transgenic mice result in 
altered cellular infiltrate and consequently a more severe disease phenotype. 
 
On comparing PARP14 function in skin inflammation and allergic airway disease, 
we observed that PARP14-deficiency results in a distinct outcome in skin 
inflammation compared to what was previously observed during allergic airway 
disease. As observed in the allergic airway disease model, the absence of 
PARP14 affects Th2 cytokine production in Stat6VTxParp14-/- mice (37). Here 
we demonstrated that inhibiting PARP activity of PARP14 does not modify IL-4 
responsive gene expression in keratinocytes. This is distinct from what has 
previously been observed in airway inflammation where PARP14 deficiency 
decreased the expression of inflammatory mediators. PARP14 is expressed both 
in mouse skin tissue and in human keratinocytes. It is not clear if the differences 
in PARP activity in keratinocytes could be due to altered ability of PARP14 to 
bind Stat6 responsive gene promoters or altered enzymatic activity affecting 
ADP-ribosylating ability of PARP14. 
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AD is predominantly a Th2 mediated disease. However, Stat6VTxParp14-/- mice 
develop severe AD like skin inflammation even with significant decreases in Th2 
cytokines compared to Stat6VT mice. In other models of AD like Nc/Nga mice, 
absence of Stat6 still resulted in the development of AD like lesions similar to that 
observed in Stat6 competent NC/Nga mice (126). Similarly, mice that are 
transgenic for IL-18 or Caspase-1 develop AD like skin lesions even on a Stat6 
deficient background (127). In both these studies, the authors observe an IFNγ-
favored skin microenvironment that is the likely cause of skin pathology. Similar 
to these studies, upon adoptive transfer of Stat6VTxParp14-/- CD4+ cells into 
Rag-/- mice we observed an increase in the IFNγ/IL-4 ratio. Stat6VTxParp14-/- 
mice also have elevated levels of IL-17A producing CD4+ cells. Altered IFNγ/IL-4 
ratio and increased IL-17A levels could contribute to disease pathology in 
Stat6VTxParp14-/- mice. These studies together with our observations suggest 
that absence of Th2 responses could also result in skin inflammation.  
  
It should be noted that the Stat6VTxParp14-/- mice lack PARP14 expression in 
all cells. PARP14 function has been investigated in T cells, B cells, 
macrophages, airway and esophageal epithelial cells (37, 44, 47, 111) though its 
function in other immune cells are yet to be explored. Several genes have been 
identified that are PARP14 dependent and Stat6 independent (42), suggesting 
that PARP14 could impact are other pathways in distinct cell types. Together, our 
findings demonstrate that PARP14 has similar effects in cytokine production in 
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multiple models of allergic inflammation, though the consequence of this altered 
cytokine response is distinct depending on the target organ. 
 
Stat6VT mice have a T cell-specific expression of constitutively active Stat6 (98). 
Our studies demonstrated that PARP14 deficiency in Stat6VT mice resulted in 
altered cytokine production with a decrease in Th2 cytokines and increase in IL-
17A (Figure 21). In B cells, the altered phenotype observed may be due to 
altered cytokines produced by T cells and also due to intrinsic PARP14 
deficiency. An impact of altered cytokine environment was increased serum IgE 
levels in Stat6VTxParp14-/- mice. Increased serum IgE produced could have an 
effect on allergic skin inflammation. Another impact of altered cytokine production 
is increased skin infiltration of monocyte/macrophage population. Together, our 
data suggests that the altered skin inflammation observed in Stat6VTxParp14-/- 
mice likely results from a combination of altered cytokines produced by T cells, 
(which includes reduced Th2 cytokines, increased IFNγ and IL-17A) along with 
elevated serum IgE levels and an increase in the monocyte/macrophage 
infiltration in the skin (Figure 21).  
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FUTURE DIRECTIONS 
 
PARP14 in eosinophilic esophagitis 
 
The data presented in this dissertation provides evidence and contributes to 
further our understanding of the function of PARP14 in esophageal epithelial 
cells. Here we determined the expression of PARP14 in EoE biopsies and 
correlated the expression of PARP14 with the expression of eotaxin-3. It will be 
important to look at the expression of PARP14 in T cells from patients with EoE, 
to establish if the expression of PARP14 is altered in immune cells along with 
esophageal cells. Moreover, we observed the expression of other PARPs in EoE 
biopsies and identified a decrease in the expression of PARP15 compared to 
control biopsies. A further study of the effects of PARP15 in regulating the 
expression of eotaxin-3 is essential in understanding the role of PARP15 in EoE.  
 
Our studies here establish that PARP14 regulates the expression of eotaxin-3 in 
esophageal epithelial cells though the mechanism by which PARP14 functions 
needs to be established. It is possible PARP14 functions in a similar manner in 
esophageal epithelial cells as it does in Th2 cells, where PARP14 is required for 
the binding of STAT6 to the Gata3 promoter and regulate its expression (37). 
This can be tested by performing chromatin immunoprecipitation (ChIP) assays 
by treating esophageal epithelial cells with PARP inhibitor or siRNA to PARP14.  
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From our initial studies on increased PARP14 and eotaxin-3 expression in EoE 
biopsies, in vivo models to further understand the mechanism of PARP14 in EoE 
are necessary. Experimental model of EoE can be induced by allergen challenge 
after epicutaneous (128) or respiratory (129) sensitization in Parp14-/- mice.  
As IL-17A is elevated in our model of allergic skin inflammation, it would also be 
key to look at the expression of IL-17A in EoE both locally in the esophageal 
tissue and systemically, in the blood.  
 
Current therapy for children with EoE is elimination diet, the most effective being 
elemental amino acid based diets (130).  Proton pump inhibitors (PPI) are 
commonly prescribed to EoE patients to reduce acid production or for their anti-
inflammatory effects, the function of which is still not understood. Omeprazole 
(PPI) decreases IL-4 stimulated eotaxin-3 expression in esophageal cells from 
patients with EoE by affecting the binding of Stat6 to the eotaxin-3 promoter (58) 
and JAK-STAT6 inhibitors block eotaxin-3 expression in esophageal fibroblasts 
and epithelial cells (131).  These studies suggest a potential for PARP14 
inhibitors to be tested as therapy for EoE as they could target the Th2 responses 
and eotaxin-3 expression. Therapeutic effects of PARP14 inhibition can be 
established by treating the experimental murine models of EoE with PARP14 
inhibitor PJ34 during the establishment of disease and after disease.  
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PARP14 and allergic skin inflammation 
 
Our study identifies a novel role of PARP14 in allergic skin inflammation where in 
contrast to what has previously been observed in allergic airway disease and in 
EoE, we demonstrate that PARP14 is required to limit severity of allergic skin 
inflammation.  In our studies, we see worse disease even with a decrease in Th2 
cytokines. Although atopic dermatitis is recognized predominantly as a Th2 
mediated disease, there are increasing studies demonstrating the involvement of 
other T helper subsets in disease pathogenesis. More recent evidence suggests 
the additional involvement of Th17 and Th22 cells in disease pathogenesis (132). 
Though IL-17 was initially identified to be present in the chronic phase of the 
disease, recent evidence on early-onset pediatric patient biopsies suggests both 
a Th2 and Th17 polarization early on (133). IL-17 could possibly play a role in 
inducing Th2 type immune responses (134). In peripheral blood from allergic 
asthma patients, a subset of Th2 cells capable of producing IL-4 and IL-17a was 
identified (135). Based on these studies, we could identify the IL-17 producers 
and determine if Th2 cells express IL-17a in our mouse model. It will also be 
important to assess the expression of other cytokines like IL-6 and IL-23 that 
promote IL17 production and demonstrate how Stat6VT T cells in the absence of 
PARP14 alter their cytokine expression.  
 
Stat6VTxParp14-/- mice have the limitation that mice lack PARP14 in all cells. 
Macrophages accumulate in the skin of both acute and chronic AD lesions (136). 
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Mast cell deficient Stat6VT mice have an increase in tissue macrophages (119). 
As it has been reported, PARP14 induces IL-4 triggered responses and has a 
protective effect in vascular disease and PARP14 deficiency in hematopoietic 
cells increases artherogenesis (111). Further understanding of the function of 
PARP14 in macrophages in our model of allergic inflammation would be 
beneficial in understanding disease pathology. To determine this we could induce 
allergic skin inflammation in Parp14-/- mice and determine the involvement of 
macrophages in the skin lesions. This model would also enable us to further 
study and delineate the specific subset – CD45+ CD3-, CD19-, NK1.1-, CD117-, 
CD11b-, CD11c-, CD49b-, FcεRIα-, Gr1- and SiglecF- that we identified in the 
skin of Stat6VT and Stat6VTxParp14-/- mice.  
 
In EoE patient biopsies, we identified an increase in the expression of PARP14 
compared to control biopsy samples. Looking forward, it would be important to 
analyze PARP1 and PARP14 expression in AD patient biopsy samples. PARP1 
has been implicated in allergic lung inflammation, contact hypersensitivity, EAE 
and arthritis (24, 28, 49, 50, 137 & 138). PARP1 delays wound healing by 
slowing down the migration of keratinocytes (139). The question of redundancy 
or compensatory mechanism among PARP family members is not well 
understood. PARP14 deficiency could alter the expression of other PARP family 
members. In the case of PARP1, an increase in the expression could delay 
wound closure, leaving AD like lesions prone to increased infections. In a recent 
study from our laboratory, we demonstrate that IL-4 by repressing fibronectin 
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expression delays reepithelialization and hence impairs wound healing (140). 
These studies suggest that healing of AD wounds could further be impaired in a 
system that lacks PARP14 expression. We could use a similar approach as 
shown by Serezani et al and punch ears of Stat6VTxParp14-/- mice and monitor 
wound healing and reepithelialization.  
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